Oligonucleotides comprising phosphorotrithioate internucleoside linkage
Phosphorotrithioate internucleoside linkages in oligonucleotides improve stability and activity by replacing both bridging oxygen atoms with sulfur, addressing the degradation issues of existing oligonucleotides and enhancing therapeutic efficacy.
Patent Information
- Application Number
- JP2024126510
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-07-31
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing oligonucleotides face challenges in stability and efficacy due to high sensitivity to nucleic acid degradation, necessitating improved phosphate backbone modifications for enhanced therapeutic potential.
Incorporation of phosphorotrithioate internucleoside linkages, where both bridging oxygen atoms of the phosphate group are replaced by sulfur, into oligonucleotide sequences, combined with DNA or RNA nucleosides and phosphate protecting groups, to enhance stability and activity.
The phosphorotrithioate modifications result in oligonucleotides with improved in vitro and in vivo activity compared to unmodified phosphorothioate analogs, offering enhanced therapeutic potential.
Smart Images

Figure 2024160282000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a compound represented by formula (I) TIFF2024160282000002.tif28128 [wherein one of the two bridging sulfur atoms is a DNA nucleoside or an RNA nucleoside (A 1 ) is bound to the 3' carbon atom of another nucleoside (A 2 ), and R is a hydrogen or a phosphate protecting group. The present invention relates to an oligonucleotide comprising at least one phosphorotrithioate internucleoside linkage of the formula: [Background technology]
[0002] Short synthetic nucleic acids have shown great potential as therapeutic agents. Since the first proof-of-concept study in the late 1970s demonstrated that unmodified deoxynucleotides inhibited virus production in vitro (PC Zamecnik, ML Stephenson, Proc. Nat. Acad. Sci. USA 1978, 75, 280-284 (Non-Patent Document 1)), significant progress has been achieved by chemical modification. Due to their high sensitivity to nucleic acid degradation, stabilization of the phosphodiester backbone of nucleic acids was the obvious starting point for chemical optimization of therapeutic oligonucleotides. As a result, phosphorothioates (PS) (F. Eckstein, Antisense and Nucleic Acid Drug Development 2009, 10, 117-121. (Non-Patent Document 2)), phosphorodithioates (e.g., WT Weisler, MH Caruthers, J. Org. Chem 1996, 61, 4272-4281. (Non-Patent Document 3)), boranophosphates (e.g., JS Summers, BR Shaw, Curr. Med. Chem. 2001, 8, 1147-1155. (Non-Patent Document 4)), (thio)phosphoramidates (e.g., S. Gryaznov, T. Skorski, C. Cucco, M. Nieborowska-Skorska, CY Chiu, D. Lloyd, J. Chen, M. Koziolkiewicz B. Calabretta, Nucleic Acids A wide variety of phosphate modifications have been explored, including phosphonates (e.g., PS Sarin, S. Agrawal, MP Civeira, J. Goodchild, T. Ikeuchi, PC Zamecnik, Proc. Nat. Acad. Sci. USA 1988, 20, 7448-7451 (Non-Patent Document 6)) and methylphosphonates (e.g., PS Sarin, S. Agrawal, MP Civeira, J. Goodchild, T. Ikeuchi, PC Zamecnik, Proc. Nat. Acad. Sci. USA 1988, 20, 7448-7451 (Non-Patent Document 7)). Among these phosphate analogues, perhaps the most successful modification is the phosphorothioate, in which one of the non-bridging phosphate oxygen atoms is replaced by sulfur.Due to their high stability against nucleases and their pharmacokinetic advantages, phosphorothioate oligonucleotides became the first generation of oligonucleotide therapeutics and paved the way for later generation modifications such as locked nucleic acids (LNA) or 2'-O-(2-methoxyethyl)-oligoribonucleotides (2'-MOE). [Prior art documents] [Non-patent literature]
[0003] [Non-Patent Document 1] PCZamecnik,MLStephenson,Proc.Nat.Acad.Sci.USA 1978,75,280-284 [Non-Patent Document 2] F. Eckstein, Antisense and Nucleic Acid Drug Development 2009,10,117-121. [Non-Patent Document 3] W. T. Weisler, M. H. Caruthers, J. Org. Chem 1996, 61, 4272-4281. [Non-Patent Document 4] JSSummers,BRShaw,Curr.Med.Chem.2001,8,1147-1155. [Non-Patent Document 5] S. Gryaznov, T. Skorski, C. Cucco, M. Nieborowska-Skorska, CYChiu, D. Lloyd, J. Chen, M. Koziolkiewicz B. Calabretta, Nucleic Acids Res. 1996, 24, 1508-1514. [Non-Patent Document 6] PS Sarin, S. Agrawal, MPCiveira, J. Goodchild, T. Ikeuchi, PC Zamecnik, Proc. Nat. Acad. Sci. USA 1988, 20, 7448-7451 Summary of the Invention
[0004] The present invention relates to (thio)phosphate modifications in which phosphorotrithioate bonds are incorporated into oligonucleotide sequences. In this type of phosphorotrithioate, not only one of the non-bridging phosphate oxygen atoms is replaced by sulfur, but also two bridging oxygen atoms at the 3' and 5' positions of the adjacent ribose sugar ring are replaced by sulfur.
[0005] Surprisingly, it has been found that just a single modification according to the invention can result in oligonucleotides with improved activity both in vitro and in vivo compared to the unmodified phosphorothioate analogue. [The present invention 1001] Formula (I) TIFF2024160282000003.tif28128 [wherein one of the two bridging sulfur atoms is a DNA nucleoside or an RNA nucleoside (A 1 ) is attached to the 3' carbon atom of another nucleoside (A 2 ), and R is a hydrogen or a phosphate protecting group. An oligonucleotide comprising at least one phosphorotrithioate internucleoside linkage. [The present invention 1002] The nucleoside (A 1 1001. The oligonucleotide of the present invention, wherein: [The present invention 1003] The nucleoside (A 2 The oligonucleotide of the present invention 1001 or 1002, wherein the nucleotide sequence of the nucleotide sequence of the present invention is a DNA nucleoside, an RNA nucleoside, or a sugar-modified nucleoside. [The present invention 1004] The nucleoside (A 2 The oligonucleotide of any one of 1001 to 1003, wherein the nucleotide sequence of the nucleotide sequence of the present invention is a DNA nucleoside or a sugar-modified nucleoside. [The present invention 1005] The oligonucleotide of the present invention 1003 or 1004, wherein the sugar-modified nucleoside is a 2' sugar-modified nucleoside. [The present invention 1006] The nucleoside (A 2 1005. The oligonucleotide of any of claims 1001 to 1005, wherein said 2'-alkoxy-RNA, in particular 2'-methoxy-RNA, 2'-alkoxyalkoxy-RNA, in particular 2'-methoxyethoxy-RNA, 2'-amino-DNA, 2'-fluoro-RNA or 2'-fluoro-ANA. [The present invention 1007] The nucleoside (A 2 ) is an LNA nucleoside. [The present invention 1008] 1007. The oligonucleotide of the invention, wherein said LNA nucleosides are independently selected from β-D-oxy LNA, 6'-methyl-β-D-oxy LNA and ENA, in particular β-D-oxy LNA. [The present invention 1009] The nucleoside (A 1 ) and (A 2 1001. The oligonucleotide of the present invention, wherein at least one of said first and second amino acids is 2'-alkoxyalkoxy-RNA. [The present invention 1010] The oligonucleotide of claim 10, wherein said 2'-alkoxyalkoxy-RNA is 2'-methoxyethoxy-RNA. [The present invention 1011] The nucleoside (A 1 ) and (A 2 5. The oligonucleotide of any one of claims 1001 to 1004, wherein both of said nucleotides are DNA nucleosides. [The present invention 1012] The oligonucleotide of any of claims 1001 to 1011, comprising a further internucleoside linkage selected from a phosphodiester internucleoside linkage, a phosphorothioate internucleoside linkage and a phosphorotrithioate internucleoside linkage of formula (I) as defined in claim 1001. [The present invention 1013] The oligonucleotide of any of claims 1001 to 1012, comprising a phosphorothioate internucleoside linkage and a further internucleoside linkage selected from the phosphorotrithioate internucleoside linkages of formula (I) defined in claim 1001. [The present invention 1014] Any of the oligonucleotides according to claims 1001 to 1013, comprising 1 to 15, in particular 1 to 5, more particularly 1, 2, 3, 4 or 5 phosphorotrithioate internucleoside linkages of formula (I) as defined in claim 1001. [The present invention 1015] all of said further internucleoside linkages are Formula -P(=S)(OR)O2-, where R is as defined in invention 1001. Any of the oligonucleotides 1001 to 1014 of the present invention, wherein the phosphorothioate internucleoside linkage is [The present invention 1016] Any of the oligonucleotides according to claims 1001 to 1015, comprising an additional nucleoside selected from DNA nucleosides, RNA nucleosides and sugar-modified nucleosides. [The present invention 1017] Any of the oligonucleotides of claims 1001 to 1016, wherein one or more nucleosides are nucleobase modified nucleosides. [The present invention 1018] The oligonucleotide of any one of claims 1001 to 1017, wherein the oligonucleotide is an antisense oligonucleotide, an siRNA, a microRNA mimetic or a ribozyme. [The present invention 1019] The oligonucleotide of any of claims 1001 to 1018, wherein the oligonucleotide is an antisense gapmer oligonucleotide. [The present invention 1020] The oligonucleotide of the present invention, wherein said phosphorotrithioate internucleoside linkage of formula (I) is in the gap region of said gapmer oligonucleotide. [The present invention 1021] The oligonucleotide of claim 1019 or 1020, wherein said gapmer oligonucleotide is an LNA gapmer, a mixed wing gapmer, or a 2'-substituted gapmer, in particular a 2'-O-methoxyethyl gapmer. [The present invention 1022] The gapmer oligonucleotide of any of claims 1019 to 1021, wherein the gapmer oligonucleotide comprises a linked nucleotide sequence of the formula 5'-FG-F'-3', where G is a region of 5 to 18 nucleosides capable of recruiting Rnase H, said region G is flanked on the 5' and 3' ends by flanking regions F and F', respectively, and regions F and F' independently comprise or consist of 1 to 7 2' sugar-modified nucleotides, wherein the nucleosides of region F adjacent to region G are 2' sugar-modified nucleosides and the nucleosides of region F' adjacent to region G are 2' sugar-modified nucleosides. [The present invention 1023] The gapmer oligonucleotide of the present invention 1022, wherein at least one phosphorotrithioate internucleoside bond of formula (I) defined in the present invention 1001 is disposed between adjacent nucleosides of region G or between region G and region F'. [The present invention 1024] The oligonucleotide of any of claims 1001 to 1023, wherein said oligonucleotide is an antisense oligonucleotide mixmer or totalmer, in particular a splice switching oligonucleotide or a microRNA inhibitor oligonucleotide. [The present invention 1025] A pharma- ceutically acceptable salt of any of the oligonucleotides of the invention 1001 to 1024, particularly a sodium or potassium salt. [The present invention 1026] A conjugate comprising any one of the oligonucleotides or pharma- ceutically acceptable salts of the present invention 1001 to 1025 and at least one conjugate moiety covalently bonded to said oligonucleotide or said pharma- ceutically acceptable salt, optionally via a linker moiety. [The present invention 1027] A pharmaceutical composition comprising any one of the oligonucleotides of the present invention 1001 to 1026, a pharma- ceutically acceptable salt or conjugate thereof, and a therapeutically inert carrier. [The present invention 1028] The oligonucleotide, pharma- ceutically acceptable salt or conjugate of any of 1001 to 1026 according to the present invention for use as a therapeutically active substance. [The present invention 1029] The oligonucleotide, pharma- ceutically acceptable salt or conjugate thereof of any of claims 1001 to 1026 for use in treating or preventing a cardiac or hematological disorder. [The present invention 1030] 23. Use of an oligonucleotide, a pharma- ceutically acceptable salt or conjugate of any of claims 1001 to 1026 for the preparation of a medicament for the treatment or prevention of cardiac or hematological disorders. [The present invention 1031] 23. Use of an oligonucleotide, a pharma- ceutically acceptable salt or conjugate of any of claims 1001 to 1026 in the treatment or prevention of cardiac or hematological disorders. [The present invention 1032] A method for treating or preventing cardiac or blood disease, comprising administering to a patient in need thereof an effective amount of the oligonucleotide, pharma- ceutically acceptable salt or conjugate of any of the present inventions 1001 to 1026. [The present invention 1033] Follow these steps: (a) coupling a 3'S-modified nucleoside phosphoramidite to the terminal 5' sulfur atom of a 5'S-modified nucleoside or oligonucleotide to form a dithiophosphite triester intermediate; (b) thioxidizing the dithiophosphite triester intermediate obtained in step a); and (c) optionally further extending said oligonucleotide A method for producing any one of the oligonucleotides of claims 1001 to 1026, comprising: [The present invention 1034] An oligonucleotide produced according to the method of the present invention. [The present invention 1035] The invention described herein. [Brief description of the drawings]
[0006] [Figure 1] FIG. 1 shows ApoB mRNA levels and intracellular oligonucleotide concentrations (uptake) in primary rat hepatocytes at a treatment concentration of 1 μM after 24 and 72 hour incubation times. [Diagram 2] FIG. 2 shows ApoB mRNA levels in the liver and kidney of C57BL / 6JbomTac female mice treated with a single 1 mg / kg dose of an oligonucleotide having a modification according to the present invention compared to saline and unmodified controls at sacrifice on day 7. [Diagram 3] FIG. 3 shows serum cholesterol levels measured in the blood of C57BL / 6JbomTac female mice on days 0, 3 and 7 after a single 1 mg / kg dose of an oligonucleotide having a modification according to the present invention compared to saline and unmodified controls. [Figure 4] Figure 4 shows oligonucleotide tissue content in the liver, kidney and heart of C57BL / 6JbomTac female mice treated with a single 1 mg / kg dose of an oligonucleotide having a modification according to the present invention compared to an unmodified control at sacrifice on day 7. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0007] As used herein, the term "alkyl", alone or in combination, refers to a straight or branched chain alkyl group having 1 to 8 carbon atoms, particularly a straight or branched chain alkyl group having 1 to 6 carbon atoms, more particularly a straight or branched chain alkyl group having 1 to 4 carbon atoms. Examples of straight and branched chain C1-C8 alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, the isomeric pentyls, isomeric hexyls, isomeric heptyls and isomeric octyls, particularly methyl, ethyl, propyl, butyl and pentyl. Particular examples of alkyl are methyl, ethyl and propyl.
[0008] The term "cycloalkyl", alone or in combination, refers to a cycloalkyl ring having 3 to 8 carbon atoms, particularly a cycloalkyl ring having 3 to 6 carbon atoms. Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, more particularly cyclopropyl and cyclobutyl. A particular example of "cycloalkyl" is cyclopropyl.
[0009] The term "alkoxy", alone or in combination, means a radical of the formula alkyl-O-, where the term "alkyl" has the meaning previously given, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy. Particular "alkoxy" are methoxy and ethoxy. Methoxyethoxy is a particular example of "alkoxyalkoxy".
[0010] The term "oxy", alone or in combination, signifies the -O- group.
[0011] The term "alkenyl", alone or in combination, denotes a straight-chain or branched hydrocarbon group containing an olefinic bond and up to 8, preferably up to 6, particularly preferably up to 4 carbon atoms. Examples of alkenyl groups are ethenyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl and isobutenyl.
[0012] The term "alkynyl", alone or in combination, means a straight-chain or branched hydrocarbon residue containing a triple bond and up to 8, in particular 2, carbon atoms.
[0013] The terms "halogen" or "halo", alone or in combination, mean fluorine, chlorine, bromine or iodine, particularly fluorine, chlorine or bromine, more particularly fluorine. The term "halo", in combination with other groups, denotes substitution of said groups with at least one halogen, particularly 1 to 5 halogens, especially 1 to 4 halogens, i.e. 1, 2, 3 or 4 halogens.
[0014] The term "haloalkyl", alone or in combination, refers to an alkyl group substituted with at least one halogen, in particular substituted with 1 to 5 halogens, in particular substituted with 1 to 3 halogens. Examples of haloalkyl include monofluoromethyl, difluoromethyl or trifluoromethyl, or monofluoroethyl, difluoroethyl or trifluoroethyl, or monofluoropropyl, difluoropropyl or trifluoropropyl, such as 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoroethyl or trifluoromethyl. Fluoromethyl, difluoromethyl and trifluoromethyl are specific "haloalkyl".
[0015] The term "halocycloalkyl", alone or in combination, means a cycloalkyl group as defined above substituted with at least one halogen, particularly substituted with 1 to 5 halogens, especially substituted with 1 to 3 halogens. Particular examples of the term "halocycloalkyl" are halocyclopropyl, particularly fluorocyclopropyl, difluorocyclopropyl and trifluorocyclopropyl.
[0016] The terms "hydroxyl" and "hydroxy", alone or in combination, refer to an --OH group.
[0017] The terms "thiohydroxyl" and "thiohydroxy", alone or in combination, refer to a -SH group.
[0018] The term "carbonyl", alone or in combination, means the -C(O)- group.
[0019] The terms "carboxy" or "carboxyl", alone or in combination, refer to a -COOH group.
[0020] The term "amino," alone or in combination, means a primary amino group (-NH2), a secondary amino group (-NH-), or a tertiary amino group (-N-).
[0021] The term "alkylamino", alone or in combination, means an amino group as defined above substituted with one or two alkyl groups, as defined above.
[0022] The term "sulfonyl", alone or in combination, means a -SO2 group.
[0023] The term "sulfinyl", alone or in combination, signifies the -SO- group.
[0024] The term "sulfanyl", alone or in combination, signifies the -S- group.
[0025] The term "cyano", alone or in combination, means the radical -CN.
[0026] The term "azido", alone or in combination, means the -N3 group.
[0027] The term "nitro", alone or in combination, means a NO2 group.
[0028] The term "formyl", alone or in combination, means the group -C(O)H.
[0029] The term "carbamoyl," alone or in combination, means the group -C(O)NH.
[0030] The term "carbamide", alone or in combination, means the group -NH-C(O)-NH.
[0031] The term "aryl," alone or in combination, denotes a monovalent aromatic carbocyclic mono- or bicyclic ring system containing 6 to 10 carbon ring atoms, optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl, and formyl. Examples of aryl include phenyl and naphthyl, especially phenyl.
[0032] The term "heteroaryl", alone or in combination, denotes a monovalent aromatic heterocyclic mono- or bicyclic ring system of 5 to 12 ring atoms containing 1, 2, 3 or 4 heteroatoms selected from N, O and S, and the remaining ring atoms are carbon optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl, and formyl. Examples of heteroaryl include pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, azepinyl, diazepinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, carbazolyl or acridinyl.
[0033] The term "heterocyclyl", alone or in combination, means a monovalent saturated or partially unsaturated monocyclic or bicyclic ring system of 4 to 12, especially 4 to 9, ring atoms containing 1, 2, 3 or 4 ring heteroatoms selected from N, O and S, and the remaining ring atoms are carbon optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl and formyl. Examples of monocyclic saturated heterocyclyls include azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydro-thienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, or oxazepanyl. Examples of bicyclic saturated heterocycloalkyl are 8-aza-bicyclo[3.2.1]octyl, quinuclidinyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 9-aza-bicyclo[3.3.1]nonyl, 3-oxa-9-aza-bicyclo[3.3.1]nonyl, or 3-thia-9-aza-bicyclo[3.3.1]nonyl. Examples of partially unsaturated heterocycloalkyl are dihydrofuryl, imidazolinyl, dihydro-oxazolyl, tetrahydro-pyridinyl, or dihydropyranyl.
[0034] The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness and properties of the free base or free acid, without being biologically or otherwise undesirable. Salts are formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, especially hydrochloric acid, and organic acids, such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine, etc. In addition, these salts can be prepared by adding an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium salts. Salts derived from organic bases include, but are not limited to, primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resin salts.The oligonucleotides of the present invention can also exist in zwitterionic form.The particularly preferred pharmaceutically acceptable salts of the present invention are sodium, lithium, potassium and trialkylammonium salts.
[0035] The term "protecting group", alone or in combination, means a group that selectively blocks a reactive site of a multifunctional compound so that a chemical reaction can be selectively carried out at an otherwise unprotected reactive site. The protecting group can be removed. Exemplary protecting groups are amino-protecting groups, carboxy-protecting groups, or hydroxy-protecting groups.
[0036] A "phosphate protecting group" is a protecting group for a phosphate group. Examples of phosphate protecting groups are 2-cyanoethyl and methyl. A specific example of a phosphate protecting group is 2-cyanoethyl.
[0037] A "hydroxyl protecting group" is a protecting group for a hydroxyl group, and is also used to protect a thiol group. Examples of hydroxyl protecting groups are acetyl (Ac), benzoyl (Bz), benzyl (Bn), β-methoxyethoxymethyl ether (MEM), dimethoxytrityl (or bis-(4-methoxyphenyl)phenylmethyl) (DMT), trimethoxytrityl (or tris-(4-methoxyphenyl)phenylmethyl) (TMT), methoxymethyl ether (MOM), methoxytrityl[(4-methoxyphenyl)diphenylmethyl (MMT), p-methoxybenzyl ether (PMB), methylthiomethyl ether, pivaloyl (Piv), tetrahydropyranyl (THP), tetrahydrofuran (THF), trityl or triphenylmethyl (Tr), silyl ethers (e.g. trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), tri-iso-propylsilyloxymethyl (TOM) and triisopropylsilyl (TIPS) ethers), methyl ether and ethoxyethyl ether (EE). Particular examples of hydroxyl protecting groups are DMT and TMT, especially DMT.
[0038] A "thiohydroxyl protecting group" is a protecting group for a thiohydroxyl group. Examples of thiohydroxyl protecting groups are those of a "hydroxyl protecting group."
[0039] If one of the starting materials or compounds of the present invention contains one or more functional groups that are not stable or reactive under the reaction conditions of one or more reaction steps, suitable protecting groups (e.g., those described in "Protective Groups in Organic Chemistry" by TW Greene and PG M Huts, 3rd Ed., 1999, Wiley, New York) can be introduced before the critical step application methods well known in the art. Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature. Examples of protecting groups are tert-butoxycarbonyl (Boc), 9-fluorenylmethylcarbamate (Fmoc), 2-trimethylsilylethylcarbamate (Teoc), carbobenzyloxy (Cbz) and p-methoxybenzyloxycarbonyl (Moz).
[0040] The compounds described herein may contain several asymmetric centers and may exist as optically pure enantiomers, mixtures of enantiomers, such as racemates, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
[0041] Oligonucleotides The term "oligonucleotide" as used herein is defined as it is generally understood by those skilled in the art as a molecule that comprises two or more covalently linked nucleosides. Such covalently linked nucleosides may also be referred to as nucleic acid molecules or oligomers. Oligonucleotides are usually produced in the laboratory by solid-phase chemical synthesis followed by purification. When referring to the sequence of an oligonucleotide, the reference is made to the sequence or order of the nucleobase moieties of the covalently linked nucleotides or nucleosides, or to modifications thereof. The oligonucleotides of the present invention are artificial, chemically synthesized, and typically purified or isolated. The oligonucleotides of the present invention may comprise one or more modified nucleosides or nucleotides.
[0042] Antisense oligonucleotides The term "antisense oligonucleotide" as used herein is defined as an oligonucleotide that can regulate the expression of a target gene by hybridizing to a target nucleic acid, particularly a continuous sequence on the target nucleic acid.Antisense oligonucleotides are not double-stranded in nature, and therefore are not siRNA or shRNA.Preferably, the antisense oligonucleotides of the present invention are single-stranded.It is understood that the single-stranded oligonucleotides of the present invention can form hairpin or intermolecular duplex structures (duplexes between two molecules of the same oligonucleotide), as long as the degree of intra or inter self-complementarity over the entire length of the oligonucleotide is less than 50%.
[0043] Contiguous nucleotide sequence The term "contiguous nucleotide sequence" refers to a region of an oligonucleotide that is complementary to a target nucleic acid. This term is used interchangeably herein with the terms "contiguous nucleobase sequence" and "oligonucleotide motif sequence." In some embodiments, all nucleotides of an oligonucleotide constitute a contiguous nucleotide sequence. In some embodiments, an oligonucleotide comprises a contiguous nucleotide sequence, e.g., an FG-F' gapmer region, and may optionally include a nucleotide linker region that can be used to attach additional nucleotides, e.g., functional groups, to the contiguous nucleotide sequence. The nucleotide linker region may or may not be complementary to the target nucleic acid.
[0044] nucleotide Nucleotides are the building blocks of oligonucleotides and polynucleotides, and for the purposes of the present invention, include both naturally occurring and non-naturally occurring nucleotides.Naturally, nucleotides, such as DNA and RNA nucleotides, contain a ribose sugar moiety, a nucleic acid base moiety and one or more phosphate groups (not present in nucleosides).Nucleosides and nucleotides can also be referred to interchangeably as "units" or "monomers".
[0045] Modified Nucleosides The term "modified nucleoside" or "nucleoside modification" as used herein refers to a nucleoside that is modified by the introduction of one or more modifications in the sugar moiety or (nucleic acid) base moiety, compared to the equivalent DNA or RNA nucleoside. In a preferred embodiment, the modified nucleoside comprises a modified sugar moiety. The term "modified nucleoside" may also be used interchangeably with the term "nucleoside analog" or modified "unit" or modified "monomer". Nucleosides with unmodified DNA or RNA sugar moieties are referred to herein as DNA or RNA nucleosides. Nucleosides with modifications in the base region of DNA or RNA nucleosides are still generally referred to as DNA or RNA if they are capable of Watson Crick base pairing.
[0046] Modified Internucleoside Linkages The term "modified internucleoside linkage" is defined as understood by those skilled in the art as a linkage other than a phosphodiester (PO) linkage that covalently links two nucleosides together. Thus, the oligonucleotide of the present invention may contain modified internucleoside linkage. In some embodiments, modified internucleoside linkage increases the nuclease resistance of the oligonucleotide compared to phosphodiester linkage. In the case of naturally occurring oligonucleotides, the internucleoside linkage comprises a phosphate group that forms a phosphodiester bond between adjacent nucleosides. Modified internucleoside linkages are particularly useful for stabilizing oligonucleotides for in vivo use and may serve to protect against nuclease cleavage in regions of DNA or RNA nucleosides of the oligonucleotide of the present invention, such as in the gap region of a gapmer oligonucleotide, and in regions of modified nucleosides, such as regions F and F'.
[0047] In one embodiment, the oligonucleotide comprises one or more internucleoside linkages modified from natural phosphodiester, e.g., such that the one or more modified internucleoside linkages are more resistant to nuclease attack. Nuclease resistance can be determined by incubating the oligonucleotide in serum or by using a nuclease resistance assay (e.g., snake venom phosphodiesterase (SVPD)), both of which are well known in the art. An internucleoside linkage that can improve the nuclease resistance of an oligonucleotide is called a nuclease-resistant internucleoside linkage. In some embodiments, at least 50% of the internucleoside linkages of the oligonucleotide, or a contiguous nucleotide sequence thereof, are modified, e.g., at least 60%, e.g., at least 70%, e.g., at least 80 or e.g., at least 90% of the internucleoside linkages of the oligonucleotide, or a contiguous nucleotide sequence thereof, are nuclease-resistant internucleoside linkages. In some embodiments, all of the internucleoside linkages of the oligonucleotide, or a contiguous nucleotide sequence thereof, are nuclease-resistant internucleoside linkages. It will be appreciated that in some embodiments, the nucleoside that links the oligonucleotide of the invention to a non-nucleotide functional group, e.g., a conjugate, may be a phosphodiester.
[0048] A preferred modified internucleoside linkage for use in the oligonucleotides of the present invention is the phosphorothioate.
[0049] Phosphorothioate internucleoside linkages are particularly useful due to their nuclease resistance, favorable pharmacokinetics and ease of manufacture. In some embodiments, at least 50% of the internucleoside linkages of the oligonucleotide, or its consecutive nucleotide sequence, are phosphorothioate, for example at least 60%, for example at least 70%, for example at least 80% or for example at least 90% of the internucleoside linkages of the oligonucleotide, or its consecutive nucleotide sequence, are phosphorothioate. In some embodiments, other than the phosphorotrithioate internucleoside linkages, all of the internucleoside linkages of the oligonucleotide, or its consecutive nucleotide sequence, are phosphorothioate. In some embodiments, the oligonucleotide of the present invention comprises both phosphorothioate internucleoside linkages and at least one phosphodiester linkage, for example 2, 3 or 4 phosphodiester linkages, in addition to the phosphorotrithioate linkages. In gapmer oligonucleotides, phosphodiester linkages, if present, are not properly located between consecutive DNA nucleosides in the gap region G.
[0050] Nuclease-resistant linkages such as phosphorothioate linkages are particularly useful in regions of oligonucleotides that can recruit nucleases when duplexed with a target nucleic acid, such as region G of a gapmer. However, phosphorothioate linkages may also be useful in non-nuclease recruiting and / or affinity enhancing regions, such as regions F and F' of a gapmer. A gapmer oligonucleotide may, in some embodiments, contain one or more phosphodiester linkages in regions F or F', or both regions F and F', and the internucleoside linkages of region G may be fully phosphorothioate.
[0051] Advantageously, all internucleoside linkages in the contiguous nucleotide sequence of the oligonucleotide, or all internucleoside linkages of the oligonucleotide, are phosphorothioate linkages.
[0052] As disclosed in EP 2 742 135, it will be appreciated that antisense oligonucleotides may contain other internucleoside linkages (other than phosphodiester and phosphorothioate), such as alkylphosphonate / methylphosphonate internucleoside linkages, which according to EP 2 742 135, for example, may be tolerated within the gap region of alternative DNA phosphorothioates.
[0053] Stereoindregular phosphorothioate bond A phosphorothioate linkage is an internucleoside phosphate linkage in which one of the non-bridging oxygens is replaced by sulfur. The replacement of one of the non-bridging oxygens with sulfur introduces a chiral center, and therefore within a single phosphorothioate oligonucleotide, each phosphorothioate internucleoside linkage can be either an S (Sp) or an R (Rp) stereoisoform. Such internucleoside linkages are called "chiral internucleoside linkages." In comparison, phosphodiester internucleoside linkages are non-chiral because they have two non-terminal oxygen atoms.
[0054] The assignment of chirality of stereocenters is determined by the standard Cahn-Ingold-Prelog rules (CIP ordering rules) first published in Cahn, RS; Ingold, CK; Prelog, V. (1966) "Specification of Molecular Chirality" Angewandte Chemie International Edition 5(4):385-415. doi:10.1002 / anie.196603851.
[0055] During standard oligonucleotide synthesis, the stereoselectivity of coupling and subsequent sulfurization is not controlled. Because of this, the stereochemistry of each phosphorothioate internucleoside bond is randomly Sp or Rp, and therefore phosphorothioate oligonucleotides produced by conventional oligonucleotide synthesis are in fact 2 XThe phosphorothioate oligonucleotides may be present in up to 10 different phosphorothioate diastereoisomers, where X is the number of phosphorothioate internucleoside linkages. Such oligonucleotides are referred to herein as stereoirregular phosphorothioate oligonucleotides and do not contain any stereoselective internucleoside linkages. Thus, stereoirregular phosphorothioate oligonucleotides are mixtures of individual diastereoisomers derived from stereospecific synthesis. In this context, the mixture may be up to 2 X are defined as different phosphorothioate diastereoisomers of
[0056] Stereospecific Internucleoside Linkages A stereodefined internucleoside linkage is a chiral internucleoside linkage that has a diastereomeric excess over one of its two diastereomeric forms, Rp or Sp.
[0057] It should be appreciated that stereoselective oligonucleotide synthesis methods used in the art typically provide at least about 90% or at least about 95% diastereoselectivity at each chiral internucleoside linkage, and thus up to about 10%, e.g., about 5%, of the oligonucleotide molecules may possess alternate diastereoisomers.
[0058] In some embodiments, the diastereomeric ratio of each stereodefined chiral internucleoside linkage is at least about 90: 10. In some embodiments, the diastereomeric ratio of each chiral internucleoside linkage is at least about 95:5.
[0059] The stereospecific phosphorothioate linkage is a specific example of a stereospecific internucleoside linkage.
[0060] Stereospecific phosphorothioate linkages A stereodefined phosphorothioate bond is a phosphorothioate bond that has a diastereomeric excess over one of its two diastereomeric forms, Rp or Sp.
[0061] The Rp and Sp configurations of the phosphorothioate internucleoside linkages are shown below: TIFF2024160282000004.tif32128
[0062] In the formula, the 3'R group represents the 3'position of the adjacent nucleoside (the 5'nucleoside) and the 5'R group represents the 5'position of the adjacent nucleoside (the 3'nucleoside).
[0063] As used herein, an Rp internucleoside linkage may also be designated as srP, and an Sp internucleoside linkage may also be designated as ssP.
[0064] In certain embodiments, the diastereomeric ratio of each stereodefined phosphorothioate linkage is at least about 90:10 or at least 95:5.
[0065] In some embodiments, the diastereomeric ratio of each stereospecific phosphorothioate linkage is at least about 97:3. In some embodiments, the diastereomeric ratio of each stereospecific phosphorothioate linkage is at least about 98:2. In some embodiments, the diastereomeric ratio of each stereospecific phosphorothioate linkage is at least about 99:1.
[0066] In some embodiments, the stereospecific internucleoside linkages are in the same diastereomeric form (Rp or Sp) in at least 97%, such as at least 98%, such as at least 99%, or (essentially) all of the oligonucleotide molecules present in the population of oligonucleotide molecules.
[0067] The diastereomeric purity can be measured in a model system that has only an achiral backbone (i.e., phosphodiester). The diastereomeric purity of each monomer can be measured, for example, by coupling a monomer with a stereospecific internucleoside linkage to the following model system "5' t-po-t-po-t-po 3'". This results in the following: 5' DMTr-t-srp-t-po-t-po-t-po 3' or 5' DMTr-t-ssp-t-po-t-po-t-po 3', which can be separated using HPLC. The diastereomeric purity is determined by integrating the UV signal from the two possible diastereoisomers and giving their ratio, for example, 98:2, 99:1 or >99:1.
[0068] It will be understood that the diastereomeric purity of a particular single diastereoisomer (a single stereodefined oligonucleotide molecule) is a function of the coupling selectivity for the defined stereocenters at each internucleoside position and the number of stereodefined internucleoside linkages to be introduced. As an example, if the coupling selectivity at each position is 97%, the resulting purity of a stereodefined oligonucleotide having 15 stereodefined internucleoside linkages is 0.97%. 15 i.e. 63% of the desired diastereoisomer compared to 37% of the other diastereoisomer. The purity of the defined diastereoisomers can be improved after synthesis by purification, for example, by HPLC, such as ion exchange chromatography or reverse phase chromatography.
[0069] In some embodiments, a stereodefined oligonucleotide refers to a population of oligonucleotides, where at least about 40%, such as at least about 50%, of the population are of a desired diastereoisomer.
[0070] Stated differently, in some embodiments, a stereospecific oligonucleotide refers to a population of oligonucleotides, at least about 40%, e.g., at least about 50%, of which consist of a desired (specific) stereospecific internucleoside linkage motif (also referred to as a stereospecific motif).
[0071] In the case of stereodefined oligonucleotides that contain both stereoirregular and stereodefined internucleoside chiral centers, the purity of the stereodefined oligonucleotide is determined by reference to the % population of oligonucleotides that retain the desired stereodefined internucleoside linkage motif, with the stereoirregular linkages being ignored in the calculation.
[0072] Nucleic acid bases The term nucleobase includes the purine (e.g., adenine and guanine) and pyrimidine (e.g., uracil, thymine and cytosine) moieties present in nucleosides and nucleotides, which form hydrogen bonds during nucleic acid hybridization. In the context of the present invention, the term nucleobase also includes modified nucleobases that may differ from naturally occurring nucleobases, but are functional during nucleic acid hybridization. In this context, "nucleobase" refers to both naturally occurring nucleobases, such as adenine, guanine, cytosine, thymidine, uracil, xanthine and hypoxanthine, and non-naturally occurring variants. Such variants are described, for example, in Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl.37 1.4.1.
[0073] In some embodiments, the nucleobase moiety is modified by changing the purine or pyrimidine to a modified purine or pyrimidine, e.g., a substituted purine or substituted pyrimidine, e.g., a nucleobase selected from isocytosine, pseudoisocytosine, 5-methylcytosine, 5-thiazolo-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil 5-thiazolo-uracil, 2-thio-uracil, 2'-thio-thymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine, and 2-chloro-6-aminopurine.
[0074] The nucleobase moiety is represented by the letter code of each corresponding nucleobase, for example, A, T, G, C or U, and each letter can optionally include a modified nucleobase of equivalent function.For example, in the exemplary oligonucleotide, the nucleobase moiety is selected from A, T, G, C and 5-methylcytosine.Optionally, 5-methylcytosine LNA nucleoside can be used in LNA gapmers.
[0075] Modified Oligonucleotides The term modified oligonucleotide describes an oligonucleotide containing one or more sugar-modified nucleosides and / or modified internucleoside linkages. The term "chimeric" oligonucleotide is a term used in the literature to describe oligonucleotides having modified nucleosides.
[0076] Stereospecific Oligonucleotides A stereospecific oligonucleotide is an oligonucleotide in which at least one of the internucleoside linkages is a stereospecific internucleoside linkage.
[0077] A stereodefined phosphorothioate oligonucleotide is an oligonucleotide in which at least one of the internucleoside linkages is a stereodefined phosphorothioate internucleoside linkage.
[0078] Complementarity The term "complementarity" describes the Watson-Crick base pairing ability of nucleosides / nucleotides. Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A)-thymine (T) / uracil (U). Oligonucleotides may contain nucleosides with modified nucleobases, for example, 5-methylcytosine is often used instead of cytosine, and thus the term complementarity will be understood to encompass Watson-Crick base pairing between unmodified and modified nucleobases (see, for example, Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl.37 1.4.1).
[0079] The term "% complementarity" as used herein refers to the percentage of nucleotides in a contiguous nucleotide sequence in a nucleic acid molecule (e.g., an oligonucleotide) that are complementary (i.e., form Watson Crick base pairs) at a given position to a contiguous nucleotide sequence in a separate nucleic acid (e.g., a target nucleic acid) at a given position. The percentage is calculated by counting the number of aligned bases that form pairs between the two sequences (when aligning the target sequence 5'-3' with the oligonucleotide sequence 3'-5'), dividing by the total number of nucleotides in the oligonucleotide, and multiplying by 100. In such a comparison, nucleic acid bases / nucleotides that do not align (form base pairs) are referred to as mismatches. Preferably, insertions and deletions are not allowed in the calculation of the % complementarity of contiguous nucleotide sequences.
[0080] The term "fully complementary" refers to 100% complementarity.
[0081] identity The term "identity" as used herein refers to the number of oligonucleotides, expressed as a percentage, in a contiguous nucleotide sequence in a nucleic acid molecule (e.g., an oligonucleotide) that is identical (i.e., in their ability to form Watson Crick base pairs with complementary nucleosides) at a given position to a contiguous nucleotide sequence in a separate nucleic acid molecule (e.g., a target nucleic acid) at a given position. The percentage is calculated by dividing the number of aligned bases that are identical between the two sequences by the total number of nucleotides in the oligonucleotide and multiplying by 100. Percent identity = (match x 100) / length of aligned region. Preferably, insertions and deletions are not allowed in the calculation of % complementarity of contiguous nucleotide sequences.
[0082] Hybridization The term "hybridizing" or "hybridizing" as used herein should be understood as two nucleic acid strands (e.g., an oligonucleotide and a target nucleic acid) forming a duplex by forming hydrogen bonds between base pairs on opposing strands. The affinity of the binding between two nucleic acid strands is the strength of hybridization. This is measured by the melting temperature (T), which is defined as the temperature at which half of the oligonucleotide forms a duplex with the target nucleic acid. m ) is often described by T m is not strictly proportional to affinity (Mergny and Lacroix, 2003, Oligonucleotides 13:515-537). The standard state Gibbs free energy, ΔG°, more accurately represents the binding affinity, ΔG°=-RTln(K d ) to calculate the dissociation constant (K d), where R is the gas constant and T is the absolute temperature. Thus, a very low ΔG° of the reaction of an oligonucleotide with a target nucleic acid reflects strong hybridization between the oligonucleotide and the target nucleic acid. ΔG° is the energy associated with a reaction at an aqueous concentration of 1M, pH of 7, and temperature of 37°C. Hybridization of an oligonucleotide to a target nucleic acid is a spontaneous reaction, and in the case of a spontaneous reaction, ΔG° is less than zero. ΔG° can be experimentally measured by isothermal titration calorimetry (ITC), for example, as described in Hansen et al., 1965, Chem. 36-38 and Holdgate et al., 2005, Drug Discov Today. Those skilled in the art will know that commercially available equipment is available for measuring ΔG°. ΔG° can also be numerically estimated using nearest neighbor models, as described in SantaLucia, 1998, Proc Natl Acad Sci USA. 95:1460-1465, using appropriately derived thermodynamic parameters as described in Sugimoto et al., 1995, Biochemistry 34:11211-11216 and McTigue et al., 2004, Biochemistry 43:5388-5405. To have the potential to modulate its intended nucleic acid target by hybridization, the oligonucleotides of the present invention hybridize to the target nucleic acid with estimated ΔG° values of less than -10 kcal for oligonucleotides of 10-30 nucleotides in length. In some embodiments, the degree or strength of hybridization is measured by the standard state Gibbs free energy ΔG°. The oligonucleotides may hybridize to the target nucleic acid with an estimated ΔG° value in the range of less than -10 kcal, such as less than -15 kcal, such as less than -20 kcal, and such as less than -25 kcal for oligonucleotides of 8 to 30 nucleotides in length. In some embodiments, the oligonucleotides hybridize to the target nucleic acid with an estimated ΔG° value of -10 to -60 kcal, such as -12 to -40, such as -15 to -30 kcal or -16 to -27 kcal, such as -18 to -25 kcal.
[0083] sugar modification Oligomers of the invention may contain one or more nucleosides having modified sugar moieties, ie, modifications in the sugar moiety as compared to the ribose sugar moiety found in DNA and RNA.
[0084] A large number of nucleosides with modifications of the ribose sugar moiety have been produced with the primary purpose of improving certain properties of oligonucleotides, such as affinity and / or nuclease resistance.
[0085] Such modifications include, for example, those in which the ribose ring structure has been modified by replacing it with a hexose ring (HNA) or bicyclic ring (typically having a biradical bridge between the C2 and C4 carbons of the ribose ring (LNA)), or an unlinked ribose ring (e.g., UNA), which typically lacks a bond between the C2 and C3 carbons. Other sugar-modified nucleosides include, for example, bicyclohexose nucleic acids (WO 2011 / 017521) or tricyclic nucleic acids (WO 2013 / 154798). Modified nucleosides also include nucleosides in which the sugar moiety has been replaced with a non-sugar moiety, for example in the case of peptide nucleic acids (PNAs), or morpholino nucleic acids.
[0086] Sugar modifications also include modifications by changing the substituents on the ribose ring to groups other than hydrogen or to the 2'-OH group naturally occurring in DNA and RNA nucleosides. Substituents can be introduced, for example, at the 2', 3', 4' or 5' position.
[0087] 2' sugar modified nucleosides A 2' sugar modified nucleoside is a nucleoside that has a substituent other than H or -OH at the 2' position (2' substituted nucleoside) or that contains a 2' linked biradical that can form a bridge between the 2' carbon and the second carbon of the ribose ring, e.g., LNA (2'-4' biradical bridge).
[0088] In fact, much attention has been paid to the development of 2'-substituted nucleosides, and many 2'-substituted nucleosides have been found to have beneficial properties when incorporated into oligonucleotides.For example, 2'-modified nucleosides can provide oligonucleotides with improved binding affinity and / or increased nuclease resistance.Examples of 2'-substituted modified nucleosides are 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA and 2'-F-ANA nucleosides. Further examples can be found, for example, in Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213, and Deleavey and Damha, Chemistry and Biology 2012, 19, 937. Below is a description of some 2'-substituted modified nucleosides. TIFF2024160282000005.tif75128
[0089] In the context of the present invention, 2' substitutions do not include 2' bridging molecules such as LNA.
[0090] Locked Nucleic Acid Nucleosides (LNA Nucleosides) "LNA nucleosides" are 2' modified nucleosides that contain a biradical (also called a "2'-4' bridge") linking the C2' and C4' of the ribose sugar ring of the nucleoside, which restricts or fixes the conformation of the ribose ring. These nucleosides are also referred to in the literature as bridged nucleic acids or bicyclic nucleic acids (BNAs). Fixing the conformation of the ribose is associated with improved hybridization affinity (duplex stabilization) when LNAs are incorporated into oligonucleotides of complementary RNA or DNA molecules. This can be routinely determined by measuring the melting temperature of the oligonucleotide / complementary duplex.
[0091] Non-limiting, exemplary LNA nucleosides include those described in WO 99 / 014226, WO 00 / 66604, WO 98 / 039352, WO 2004 / 046160, WO 00 / 047599, WO 2007 / 134181, WO 2010 / 077578, WO 2010 / 036698, WO 2007 / 090071, WO 2009 / 006478, WO 2011 / 156202, WO 2008 / 154401, WO 2009 / 067647, WO 2008 / 150729, Morita et al. al., Bioorganic & Med. Chem. Lett. 12, 73-76, Seth et al. J. Org. Chem. 2010, Vol 75(5) pp. 1569-81 and Mitsuoka et al., Nucleic Acids Research 2009, 37(4), 1225-1238.
[0092] The 2'-4' bridge contains from 2 to 4 bridging atoms and is particularly of the formula -XY-, where X is attached to C4' and Y is attached to C2'; During the ceremony, X is oxygen, sulfur, -CR a R b -, -C(R a )=C(R b )-, -C(=CR a R b )-, -C(R a )=N-, -Si(R a )2-, -SO2-, -NR a -;-O-NR a -, -NR a -O-, -C(=J)-, Se, -O-NR a -, -NR a -CR a R b -, -N(R a )-O- or -O-CR a R b - and Y is oxygen, sulfur, -(CR a R b ) n -, -CRa R b -O-CR a R b -, -C(R a )=C(R b )-, -C(R a )=N-, -Si(R a )2-, -SO2-, -NR a -, -C(=J)-, Se, -O-NR a -, -NR a -CR a R b -, -N(R a )-O- or -O-CR a R b - and However, -XY- is -OO-, Si(R a )2-Si(R a )2-, -SO2-SO2-, -C(R a )=C(R b )-C(R a )=C(R b ), -C(R a )=NC(R a )=N-, -C(R a )=NC(R a )=C(R b ), -C(R a )=C(R b )-C(R a )=N- or -Se-Se-, J is oxygen, sulfur, =CH2 or =N(R a ) and R a and R bis hydrogen, halogen, hydroxyl, cyano, thiohydroxyl, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl, formyl, aryl, heterocyclyl, amino, alkylamino, carbamoyl, alkylaminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, alkylcarbonylamino, carbamido, alkanoyloxy, sulfonyl, alkylsulfonyloxy, nitro, azido, thiohydroxyl sulfidoalkylsulfanyl, aryloxycarbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxycarbonyl, heteroaryloxy, heteroarylcarbonyl, -OC(=X a )R c , -OC(=X a )NR c R d and -NR e C(=X a )NR c R d are independently selected from Or, two geminal R a and R b taken together form an optionally substituted methylene, or Or, two geminal R a and R b together with the carbon atom to which they are attached form a cycloalkyl or halocycloalkyl with only one carbon atom of -XY-; wherein the substituted alkyl, substituted alkenyl, substituted alkynyl, substituted alkoxy and substituted methylene are alkyl, alkenyl, alkynyl and methylene substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl, formyl, heterocyclyl, aryl and heteroaryl; X a is oxygen, sulfur or -NRc and R c , R d and R e is independently selected from hydrogen and alkyl; n is 1, 2 or 3.
[0093] In further particular embodiments of the invention, X is oxygen, sulfur, -NR a -, -CR a R b -or-C(=CR a R b )—, in particular oxygen, sulfur, —NH—, —CH2— or —C(═CH2)—, more in particular oxygen.
[0094] In another particular embodiment of the invention, Y is -CR a R b -, -CR a R b -CR a R b -OR-CR a R b -CR a R b -CR a R b -, in particular -CH2-CHCH3-, -CHCH3-CH2-, -CH2-CH2- or -CH2-CH2-CH2-.
[0095] In certain embodiments of the present invention, -XY- is -O-(CR a R b ) n -,-S-CR a R b -, -N(R a )CR a R b -, -CR a R b -CR a R b -, -O-CR a R b -O-CR a R b -, -CR a R b -O-CR a R b-, -C(=CR a R b )-CR a R b -, -N(R a )CR a R b -,-ON(R a )-CR a R b -or-N(R a )-O-CR a R b -It is.
[0096] In certain embodiments of the present invention, R a and R b are independently selected from the group consisting of hydrogen, halogen, hydroxyl, alkyl and alkoxyalkyl, particularly hydrogen, halogen, alkyl and alkoxyalkyl.
[0097] In another embodiment of the present invention, R a and R b are independently selected from the group consisting of hydrogen, fluoro, hydroxyl, methyl and -CH2-O-CH3, in particular hydrogen, fluoro, methyl and -CH2-O-CH3.
[0098] Advantageously, R of -XY- a and R b is as defined above, and the others are all simultaneously hydrogen.
[0099] In a further particular embodiment of the invention, R a is hydrogen or alkyl, in particular hydrogen or methyl.
[0100] In another particular embodiment of the present invention, R b is hydrogen or alkyl, in particular hydrogen or methyl.
[0101] In certain embodiments of the present invention, R a and R b One or both of are hydrogen.
[0102] In certain embodiments of the present invention, R a and R b Only one of the groups is hydrogen.
[0103] In one particular embodiment of the invention, R a and R b One of these is methyl and the other is hydrogen.
[0104] In certain embodiments of the present invention, R a and R b are both simultaneously methyl.
[0105] In certain embodiments of the invention, -XY- is -O-CH2-, -S-CH2-, -S-CH(CH3)-, -NH-CH2-, -O-CH2CH2-, -O-CH(CH2-O-CH3)-, -O-CH(CH2CH3)-, -O-CH(CH3)-, -O-CH2-O-CH2-, -O-CH2-O-CH2-, -CH2-O-CH2-, -C(=CH2)CH2-, -C(=CH2)CH(CH3)-, -N(OCH3)CH2- or -N(CH3)CH2-.
[0106] In certain embodiments of the present invention, -XY- is -O-CR a R b -, wherein R a and R b are independently selected from the group consisting of hydrogen, alkyl and alkoxyalkyl, in particular hydrogen, methyl and -CH2-O-CH3.
[0107] In certain embodiments, -XY- is -O-CH2- or -O-CH(CH3)-, in particular -O-CH2-.
[0108] The 2'-4' bridge can be positioned either below the plane of the ribose ring (β-D-configuration) or above the plane of the ring (α-L-configuration), as shown in Formula (A) and Formula (B), respectively.
[0109] The LNA nucleosides according to the invention are in particular those of formula (B1) or (B2) TIFF2024160282000006.tif38128[In the formula, W is oxygen, sulfur, -N(R a )-or-CR a R b -, especially oxygen, B is a nucleobase or a modified nucleobase, Z is an internucleoside linkage to an adjacent nucleoside or to the 5'-terminus; Z * is an internucleoside linkage to an adjacent nucleoside or to the 3' end group, R 1 , R 2 , R 3 , R 5 and R 5* are independently selected from hydrogen, halogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkyl, azido, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl, formyl, and aryl; X, Y, R a and R b is as defined above] It is of the following.
[0110] In certain embodiments, in the definition of -XY-, R a is hydrogen or alkyl, in particular hydrogen or methyl. In another particular embodiment, in the definition of -XY-, R b is hydrogen or alkyl, in particular hydrogen or methyl. In a further particular embodiment, in the definition of -XY-, R a and R b In certain embodiments, in the definition of -XY-, one or both of R a and R b In one particular embodiment, in the definition of -XY-, only one of R a and R b In certain embodiments, in the definition of -XY-, one of R a and R bare both simultaneously methyl.
[0111] In a further particular embodiment, in the definition of X, R a is hydrogen or alkyl, in particular hydrogen or methyl. In another particular embodiment, in the definition of X, R b is hydrogen or alkyl, in particular hydrogen or methyl. In certain embodiments, in the definition of X, R a and R b In certain embodiments, in the definition of X, one or both of R a and R b In one particular embodiment, in the definition of X, only one of R a and R b In certain embodiments, in the definition of X, one of R a and R b are both simultaneously methyl.
[0112] In a further particular embodiment, in the definition of Y, R a is hydrogen or alkyl, in particular hydrogen or methyl. In another particular embodiment, in the definition of Y, R b is hydrogen or alkyl, in particular hydrogen or methyl. In certain embodiments, in the definition of Y, R a and R b In certain embodiments, in the definition of Y, one or both of R a and R b In one particular embodiment, in the definition of Y, only one of R a and R b In certain embodiments, in the definition of Y, one of R a and R b are both simultaneously methyl.
[0113] In certain embodiments of the present invention, R 1 , R 2 , R 3 , R 5 and R 5*are independently selected from hydrogen and alkyl, particularly hydrogen and methyl.
[0114] In a further particular advantageous embodiment of the invention, R 1 , R 2 , R 3 , R 5 and R 5* are all simultaneously hydrogen.
[0115] In another particular embodiment of the present invention, R 1 , R 2 , R 3 are all hydrogen at the same time, and R 5 and R 5* One of these is hydrogen and the other is as defined above, in particular alkyl, more in particular methyl.
[0116] In certain embodiments of the present invention, R 5 and R 5* are independently selected from hydrogen, halogen, alkyl, alkoxyalkyl and azide, in particular from hydrogen, fluoro, methyl, methoxyethyl and azide. In a particularly advantageous embodiment of the invention, R 5 and R 5* is hydrogen and the other is alkyl, particularly methyl, halogen, particularly fluoro, alkoxyalkyl, particularly methoxyethyl or azido, or R 5 and R 5* are both simultaneously hydrogen or halogen, in particular both simultaneously hydrogen or fluoro. In certain such embodiments, W may advantageously be oxygen and -XY- may advantageously be -O-CH2-.
[0117] In certain embodiments of the invention, -XY- is -O-CH2-, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5*are all simultaneously hydrogen. Such LNA nucleosides are disclosed in WO 99 / 014226, WO 00 / 66604, WO 98 / 039352 and WO 2004 / 046160, all of which are incorporated herein by reference, and include what are commonly known in the art as β-D-oxy LNA and α-L-oxy LNA nucleosides.
[0118] In another particular embodiment of the invention, -X-Y- is -S-CH-, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5* are all simultaneously hydrogen. Such thio LNA nucleosides are disclosed in WO 99 / 014226 and WO 2004 / 046160, which are incorporated herein by reference.
[0119] In another particular embodiment of the invention, -XY- is -NH-CH2-, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5* are all simultaneously hydrogen. Such amino LNA nucleosides are disclosed in WO 99 / 014226 and WO 2004 / 046160, which are incorporated herein by reference.
[0120] In another particular embodiment of the invention, -XY- is -O-CHCH- or -OCHCHCH-, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5*are all simultaneously hydrogen. Such LNA nucleosides are disclosed in WO 00 / 047599 and Morita et al., Bioorganic & Med. Chem. Lett. 12, 73-76, which are incorporated herein by reference, and include those commonly known in the art as 2'-O-4'C-ethylene-bridged nucleic acids (ENA).
[0121] In another particular embodiment of the invention, -XY- is -O-CH2-, W is oxygen, and R 1 , R 2 , R 3 are all hydrogen at the same time, and R 5 and R 5* is hydrogen and the other is not hydrogen but is alkyl, e.g., methyl. Such 5'-substituted LNA nucleosides are disclosed in WO 2007 / 134181, which is incorporated herein by reference.
[0122] In another particular embodiment of the invention, -XY- is -O-CR a R b - and R a and R b is not hydrogen, in particular alkyl, e.g. methyl; W is oxygen; R 1 , R 2 , R 3 are all hydrogen at the same time, and R 5 and R 5* is hydrogen and the other is not hydrogen, in particular alkyl, e.g. methyl. Such bis-modified LNA nucleosides are disclosed in WO 2010 / 077578, which is incorporated herein by reference.
[0123] In another particular embodiment of the invention, -X-Y- is -O-CHR a -, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5*are all simultaneously hydrogen. Such 6'-substituted LNA nucleosides are disclosed in WO 2010 / 036698 and WO 2007 / 090071, both of which are incorporated herein by reference. In such 6'-substituted LNA nucleosides, R a is C1-C6 alkyl, particularly methyl.
[0124] In another specific embodiment of the invention, -XY- is -O-CH(CH2-O-CH3)- ("2'O-Methoxyethyl Bicyclic Nucleic Acid", Seth et al. J. Org. Chem. 2010, Vol 75(5) pp. 1569-81).
[0125] In another specific embodiment of the invention, -XY- is -O-CH(CH2CH3)-.
[0126] In another particular embodiment of the invention, -XY- is -O-CH(CH2-O-CH3)-, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5* are all simultaneously hydrogen. Such LNA nucleosides, also known in the art as cyclic MOE (cMOE), are disclosed in WO 2007 / 090071.
[0127] In another specific embodiment of the invention, -XY- is -O-CH(CH3)- ("2'O-ethyl bicyclic nucleic acid", Seth et al. J. Org. Chem. 2010, Vol 75(5) pp. 1569-81).
[0128] In another particular embodiment of the invention, -XY- is -O-CH2-O-CH2- (Seth et al. J. Org. Chem. 2010, cited above).
[0129] In another particular embodiment of the invention, -XY- is -O-CH(CH3)-, W is oxygen, and R 1 , R2 , R 3 , R 5 and R 5* are all simultaneously hydrogen. Such 6' methyl LNA nucleosides are also known in the art as cET nucleosides and can be either the (S)-cET or (R)-cET diastereoisomers, as disclosed in WO 2007 / 090071 (β-D) and WO 2010 / 036698 (α-L), both of which are incorporated herein by reference.
[0130] In another particular embodiment of the invention, -XY- is -O-CR a R b - and R a Also b is not hydrogen, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5* are all simultaneously hydrogen. In certain embodiments, R a and R b are both simultaneously alkyl, in particular both simultaneously methyl. Such 6' disubstituted LNA nucleosides are disclosed in WO 2009 / 006478, which is incorporated herein by reference.
[0131] In another particular embodiment of the invention, -X-Y- is -S-CHR a -, W is oxygen, and R 1 , R 2 , R 3、 R 5 and R 5* are all simultaneously hydrogen. Such 6'-substituted LNA nucleosides are disclosed in WO 2011 / 156202, which is incorporated herein by reference. In certain embodiments of such 6'-substituted thio LNAs, R a is alkyl, in particular methyl.
[0132] In certain embodiments of the invention, -XY- is -C(=CH2)C(R a Rb )-, -C(=CHF)C(R a R b )- or -C(CF2)C(R a R b )-, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time. a and R b are advantageously independently selected from hydrogen, halogen, alkyl and alkoxyalkyl, in particular hydrogen, methyl, fluoro and methoxymethyl. a and R b In particular, both are hydrogen or methyl or R a and R b One of the is hydrogen and the other is methyl. Such vinyl carbo LNA nucleosides are disclosed in WO 2008 / 154401 and WO 2009 / 067647, both of which are incorporated herein by reference.
[0133] In certain embodiments of the present invention, -XY- is -N(OR a )-CH2-, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5* are all simultaneously hydrogen. In certain embodiments, R a is alkyl, e.g., methyl. Such LNA nucleosides, also known as N-substituted LNAs, are disclosed in WO 2008 / 150729, which is incorporated herein by reference.
[0134] In certain embodiments of the present invention, -XY- is -ON(R a )-, -N(R a )-O-, -NR a -CR a R b -CR a R b -OR-NR a -CRa R b -, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time. a and R b are advantageously independently selected from hydrogen, halogen, alkyl and alkoxyalkyl, in particular hydrogen, methyl, fluoro and methoxymethyl. In a particular embodiment, Ra is alkyl, e.g., methyl, and R b is hydrogen or methyl, in particular hydrogen (Seth et al. J. Org. Chem. 2010, cited above).
[0135] In a particular embodiment of the invention, -XY- is -ON(CH3)- (Seth et al. J. Org. Chem. 2010, cited above).
[0136] In certain embodiments of the present invention, R 5 and R 5* are both simultaneously hydrogen. In another particular embodiment of the present invention, R 5 and R 5* One of R is hydrogen and the other is alkyl, e.g., methyl. In such embodiments, R 1 , R 2 and R 3 may in particular be hydrogen, -XY- may in particular be -O-CH2- or -O-CHC(R a )3-, for example -O-CH(CH3)-.
[0137] In certain embodiments of the invention, -XY- is -CR a R b -O-CR a R b -, for example -CH2-O-CH2-, W is oxygen, R 1 , R 2 , R 3 , R 5 and R 5* are all simultaneously hydrogen. In certain such embodiments, Ra is in particular alkyl, e.g. methyl, R b may be hydrogen or methyl, in particular hydrogen. Such LNA nucleosides, also known as conformationally restricted nucleotides (CRN), are disclosed in WO 2013 / 036868, which is incorporated herein by reference.
[0138] In certain embodiments of the present invention, -XY- is -O-CR a R b -O-CR a R b -, for example -O-CH2-O-CH2-, W is oxygen, R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time. a and R b are advantageously independently selected from hydrogen, halogen, alkyl and alkoxyalkyl, in particular hydrogen, methyl, fluoro and methoxymethyl. In certain such embodiments, R a is in particular alkyl, e.g. methyl, R b may be hydrogen or methyl, in particular hydrogen. Such LNA nucleosides, also known as COC nucleotides, are disclosed in Mitsuoka et al., Nucleic Acids Research 2009, 37(4), 1225-1238, which is incorporated herein by reference.
[0139] It will be appreciated that unless otherwise specified, LNA nucleosides may be in the β-D or α-L stereoisoform.
[0140] Specific examples of LNA nucleosides of the present invention are shown in Scheme 1, where B is as defined above. Scheme 1 TIFF2024160282000007.tif213129TIFF2024160282000008.tif228123TIFF2024160282000009.tif142128
[0141] Particular LNA nucleosides are β-D-oxy-LNA, 6'-methyl-β-D-oxy LNA, such as (S)-6'-methyl-β-D-oxy-LNA ((S)-cET) and ENA.
[0142] RNase H activity and recruitment RNase H activity of an antisense oligonucleotide refers to its ability to recruit RNase H when it forms a duplex with a complementary RNA molecule. WO 01 / 23613 provides an in vitro method for determining RNase H activity, which can be used to determine the ability to recruit RNase H. Typically, an oligonucleotide is considered capable of recruiting RNase H when provided with a complementary target nucleic acid if it has at least 5%, e.g., at least 10% or more than 20%, of the initial rate, measured in pmol / l / min, determined when using an oligonucleotide having the same base sequence as the modified oligonucleotide being tested, but containing only DNA monomers and having phosphorothioate linkages between all monomers of the oligonucleotide, and using the methodology provided by Examples 91-95 of WO 01 / 23613 (herein incorporated by reference). Recombinant human RNase H1 is available from Lubio Science GmbH, Lucerne, Switzerland, for use in measuring RNase H activity.
[0143] Gapmar The antisense oligonucleotide of the present invention, or the contiguous nucleotide sequence thereof, may be a gapmer. Antisense gapmers are typically used to inhibit target nucleic acids via RNase H-mediated degradation. Gapmer oligonucleotides contain at least three distinct structural regions, 5'-flank, gap and 3'-flank, FG-F', in a 5'->3' orientation. The "gap" region (G) contains a stretch of contiguous DNA nucleotides that allows the oligonucleotide to recruit RNase H. The gap region is flanked by a 5'-flanking region (F) that contains one or more sugar-modified nucleosides, advantageously high affinity sugar-modified nucleosides, and a 3'-flanking region (F') that contains one or more sugar-modified nucleosides, advantageously high affinity sugar-modified nucleosides. The one or more sugar-modified nucleosides of regions F and F' enhance the affinity of the oligonucleotide to the target nucleic acid (i.e., it is an affinity-enhancing sugar-modified nucleoside). In some embodiments, one or more sugar modified nucleosides of regions F and F' are 2' sugar modified nucleosides, e.g., high affinity 2' sugar modifications, independently selected from LNA and 2'-MOE.
[0144] In a gapmer design, the 5' and 3' most nucleosides of the gap region are DNA nucleosides, each positioned adjacent to a 5' (F) or 3' (F') sugar-modified nucleoside. The flanks may be further defined by having at least one sugar-modified nucleoside at the end furthest from the gap region, i.e., at the 5' end of the 5' flank and at the 3' end of the 3' flank.
[0145] The regions FG-F' form a contiguous nucleotide sequence.The antisense oligonucleotide of the invention, or the contiguous nucleotide sequence thereof, may comprise a gapmer region of the formula FG-F'.
[0146] The total length of the gapmer designed FG-F' may be, for example, 12 to 32 nucleosides, for example, 13 to 24, for example, 14 to 22 nucleosides, for example, 14 to 17, for example, 16 to 18 nucleosides.
[0147] By way of example, a gapmer oligonucleotide of the invention can be represented by the following formula: F 1-8 -G 5-16 -F' 1-8 ,for example F 1-8 -G 7-16 -F' 2-8 However, the total length of the gapmer region FG-F' is at least 12, for example at least 14, nucleotides in length.
[0148] Regions F, G and F' are further defined below and can be incorporated into the formula FG-F'.
[0149] Gapmer region G The region G (gap region) of a gapmer is a region of nucleosides, typically DNA nucleosides, that enable the oligonucleotide to recruit RNase H, e.g., human RNase H1. RNase H is a cellular enzyme that recognizes a duplex between DNA and RNA and enzymatically cleaves the RNA molecule. A suitable gapmer may have a gap region (G) of at least 5 or 6 contiguous DNA nucleosides, e.g., 5-16 contiguous DNA nucleosides, e.g., 6-15 contiguous DNA nucleosides, e.g., 7-14 contiguous DNA nucleosides, e.g., 8-12 contiguous DNA nucleotides, e.g., 8-12 contiguous DNA nucleotides in length. The gap region G may, in some embodiments, consist of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 contiguous DNA nucleosides. The cytosine (C) DNA in the gap region may optionally be methylated, such residues being 5-methyl-cytosine ( me It is annotated as e) instead of C or c. Methylation of cytosine DNA within the gap is favored when a cg dinucleotide is present within the gap reducing potential toxicity, and this modification does not significantly affect the efficacy of the oligonucleotide.
[0150] In some embodiments, the gap region G may consist of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 consecutive phosphorothioate-linked DNA nucleosides. In some embodiments, all internucleoside linkages within the gap are phosphorothioate linkages.
[0151] Although traditional gapmers have a DNA gap region, there are many examples of modified nucleosides that allow RNaseH recruitment when used within the gap region.Modified nucleosides that have been reported as being able to recruit RNaseH when included within the gap region include, for example, α-L-LNA, C4' alkylated DNA (described in PCT / EP2009 / 050349 and Vester et al., Bioorg.Med.Chem.Lett.18(2008)2296-2300, both of which are incorporated herein by reference), arabinose-derived nucleosides such as ANA and 2'F-ANA (Mangos et al.2003 J.AM.CHEM.SOC.125,654-661), UNA (unlocked nucleic acid) (described in Fluiter et al., Mol.Biosyst.,2009,10,1039, which is incorporated herein by reference). UNAs are typically unlocked nucleic acids in which the bond between C2 and C3 of the ribose has been removed to form an unlocked "sugar" residue. The modified nucleosides used in such gapmers can be nucleosides that adopt a 2'endo (DNA-like) structure when introduced into the gap region (i.e., modifications that allow RNase H recruitment). In some embodiments, the DNA gap region (G) described herein may optionally contain 1-3 sugar modified nucleosides that adopt a 2'endo (DNA-like) structure when introduced into the gap region.
[0152] Area G - "Gap Breaker" Alternatively, there are many reports of inserting modified nucleosides that confer a 3'-end conformation to the gap region of the gapmer while retaining some RNaseH activity. Such gapmers with a gap region containing one or more 3'-end modified nucleosides are referred to as "gap breaker" or "gap-disrupting" gapmers. See, for example, WO 2013 / 022984. Gap breaker oligonucleotides retain a sufficient region of DNA nucleosides within the gap region to allow RNaseH recruitment. The ability of a gap breaker oligonucleotide design to recruit RNaseH is typically sequence or compound specific - see Rukov et al. 2015 Nucl.Acids Res.Vol.43 pp.8476-8487, which discloses "gap breaker" oligonucleotides that recruit RNaseH, in some cases providing more specific cleavage of the target RNA. Modified nucleosides used within the gap region of a gap breaker oligonucleotide may be, for example, a modified nucleoside that confers a 3' endo conformation, such as a 2'-O-methyl (OMe) or 2'-O-MOE (MOE) nucleoside, or a β-D LNA nucleoside (in which the bridge between the C2' and C4' of the ribose sugar ring of the nucleoside is in a β conformation), such as a β-D-oxy LNA or ScET nucleoside.
[0153] Similar to the gapmers containing region G described above, gap breakers or gap disrupting gapmers have a DNA nucleoside at the 5'-end of the gap (adjacent to the 3' nucleoside of region F) and a DNA nucleoside at the 3'-end of the gap (adjacent to the 5' nucleoside of region F'). Gapmers containing disruptive gaps typically retain a region of at least three or four contiguous DNA nucleosides at either the 5'- or 3'-end of the gap region.
[0154] Exemplary designs of gap breaker oligonucleotides include: F 1-8 -[D3-4 -E1-D 3-4 ] - F' 1-8 F 1-8 -[D 1-4 -E1-D 3-4 ]-F' 1-8 F 1-8 -[D 3-4 -E1-D 1-4 ]-F' 1-8 The region G includes [D n -E r -D m ], D is a consecutive sequence of DNA nucleosides, E is a modified nucleoside (gap breaker or gap disrupting nucleoside), and F and F' are flanking regions as defined herein, with the proviso that the total length of the gapmer region FG-F' is at least 12, e.g., 14, nucleotides in length.
[0155] In some embodiments, region G of the gap breaking gapmer comprises at least 6 DNA nucleosides, for example 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 DNA nucleosides. As noted above, the DNA nucleosides may be contiguous and, optionally, interspersed with one or more modified nucleosides, provided that the gap region G is capable of mediating RNase H recruitment.
[0156] Gapmer-flanking regions, F and F' Region F is positioned immediately adjacent to the 5' DNA nucleoside of region G. The 3'-most nucleoside of region F is a sugar-modified nucleoside, e.g., a high affinity sugar-modified nucleoside, e.g., a 2'-substituted nucleoside, e.g., an MOE nucleoside, or an LNA nucleoside.
[0157] Region F' is positioned immediately adjacent to the 3' DNA nucleoside of region G. The 5'-most nucleoside of region F' is a sugar-modified nucleoside, e.g., a high affinity sugar-modified nucleoside, e.g., a 2'-substituted nucleoside, e.g., an MOE nucleoside, or an LNA nucleoside.
[0158] Region F is 1 to 8 contiguous nucleotides in length, such as 2 to 6, such as 3 to 4 contiguous nucleotides in length. Advantageously, the 5'-most nucleoside of region F is a sugar-modified nucleoside. In some embodiments, the two 5'-most nucleosides of region F are sugar-modified nucleosides. In some embodiments, the two 5'-most nucleosides of region F are LNA nucleosides. In some embodiments, the two 5'-most nucleosides of region F are LNA nucleosides. In some embodiments, the two 5'-most nucleosides of region F are 2'-substituted nucleosides, such as two 3'MOE nucleosides. In some embodiments, the 5'-most nucleosides of region F are 2'-substituted nucleosides, such as MOE nucleosides.
[0159] Region F' is 2 to 8 contiguous nucleotides in length, such as 3 to 6, such as 4 to 5 contiguous nucleotides in length. Advantageously, the 3'-most nucleosides of region F' are sugar-modified nucleosides. In some embodiments, the two 3'-most nucleosides of region F' are sugar-modified nucleosides. In some embodiments, the two 3'-most nucleosides of region F' are LNA nucleosides. In some embodiments, the 3'-most nucleosides of region F' are LNA nucleosides. In some embodiments, the two 3'-most nucleosides of region F' are 2'-substituted nucleosides, such as two 3' MOE nucleosides. In some embodiments, the 3'-most nucleosides of region F' are 2'-substituted nucleosides, such as MOE nucleosides.
[0160] It should be noted that when the length of region F or region F' is 1, it is an LNA nucleoside.
[0161] In some embodiments, region F and region F' independently consist of or comprise a contiguous sequence of sugar-modified nucleosides. In some embodiments, the sugar-modified nucleosides of region F may be independently selected from 2'-O-alkyl-RNA units, 2'-O-methyl-RNA, 2'-amino-DNA units, 2'-fluoro-DNA units, 2'-alkoxy-RNA, MOE units, LNA units, arabinonucleic acid (ANA) units and 2'-fluoro-ANA units.
[0162] In some embodiments, region F and region F' independently comprise both LNA and 2'-substituted modified nucleosides (mixed wing design).
[0163] In some embodiments, region F and region F' are composed of only one type of sugar modified nucleoside, for example only MOE, or only β-D-oxy LNA, or only ScET. Such designs are also called uniform flank or uniform gapmer designs.
[0164] In some embodiments, all nucleosides of regions F or F', or F and F', are LNA nucleosides, e.g., independently selected from β-D-oxy LNA, ENA, or ScET nucleosides. In some embodiments, region F consists of 1-5, e.g., 2-4, e.g., 3-4, e.g., 1, 2, 3, 4, or 5 contiguous LNA nucleosides. In some embodiments, all nucleosides of regions F and F' are β-D-oxy LNA nucleosides.
[0165] In some embodiments, all nucleosides of region F or F', or F and F', are 2'-substituted nucleosides, such as OMe or MOE nucleosides. In some embodiments, region F consists of 1, 2, 3, 4, 5, 6, 7 or 8 consecutive OMe or MOE. In some embodiments, only one of the flanking regions can consist of 2'-substituted nucleosides, such as OMe or MOE nucleosides. In some embodiments, it is the 5' (F) flanking region that consists of 2'-substituted nucleosides, such as OMe or MOE, while the 3' (F') flanking region comprises at least one LNA nucleoside, such as a β-D-oxyLNA nucleoside or a cET nucleoside. In some embodiments, it is the 3' (F') flanking region that consists of a 2' substituted nucleoside, such as OMe or MOE, while the 5' (F) flanking region comprises at least one LNA nucleoside, such as a β-D-oxyLNA nucleoside or a cET nucleoside.
[0166] In some embodiments, all modified nucleosides in regions F and F' are LNA nucleosides, e.g., LNA nucleosides independently selected from β-D-oxy LNA, ENA, or ScET nucleosides, and regions F or F', or F and F', may optionally include DNA nucleosides (alternating flanks, see these definitions for more details). In some embodiments, all modified nucleosides in regions F and F' are β-D-oxy LNA nucleosides, and regions F or F', or F and F', may optionally include DNA nucleosides (alternating flanks, see these definitions for more details).
[0167] In some embodiments, the 5'-most and 3'-most nucleosides of regions F and F' are LNA nucleosides, such as β-D-oxyLNA nucleosides or ScET nucleosides.
[0168] In some embodiments, the internucleoside linkage between region F and region G is a phosphorothioate internucleoside linkage. In some embodiments, the internucleoside linkage between region F' and region G is a phosphorothioate internucleoside linkage. In some embodiments, the internucleoside linkage between regions F or F', F and F' is a phosphorothioate internucleoside linkage.
[0169] Further gapmer designs are disclosed in WO 2004 / 046160, WO 2007 / 146511 and WO 2008 / 113832, which are incorporated herein by reference.
[0170] LNA gapmer An LNA gapmer is a gapmer which comprises or consists of LNA nucleosides in either one or both of regions F and F'. A β-D-oxy gapmer is a gapmer which comprises or consists of β-D-oxy LNA nucleosides in either one or both of regions F and F'.
[0171] In some embodiments, the LNA gapmer has the formula: [LNA] 1-5 -[Area G]-[LNA] 1-5 and region G is as defined in the definition of gapmer region G.
[0172] MOE Gapmar An MOE gapmer is a gapmer in which regions F and F' consist of MOE nucleosides. In some embodiments, an MOE gapmer has the design [MOE] 1-8 -[Area G]-[MOE] 1-8 , e.g. [MOE] 2-7 -[Area G] 5-16 -[MOE] 2-7 , e.g. [MOE] 3-6 -[Area G]-[MOE] 3-6and region G is as defined in the gapmer definition. MOE gapmers with the 5-10-5 design (MOE-DNA-MOE) are widely used in the art.
[0173] Mixed Wing Gappar A mixed wing gapmer is an LNA gapmer in which one or both of regions F and F' comprise 2'-substituted nucleosides, e.g., MOE nucleosides, independently selected from 2'-O-alkyl-RNA units, 2'-O-methyl-RNA, 2'-amino-DNA units, 2'-fluoro-DNA units, 2'-alkoxy-RNA, MOE units, arabinonucleic acid (ANA) units and 2'-fluoro-ANA units. In some embodiments in which at least one of regions F and F', or both of regions F and F' comprise at least one LNA nucleoside, the remaining nucleosides of regions F and F' are independently selected from the group consisting of MOE and LNA. In some embodiments in which at least one of regions F and F', or both of regions F and F' comprise at least two LNA nucleosides, the remaining nucleosides of regions F and F' are independently selected from the group consisting of MOE and LNA. In some mixed wing embodiments, one or both of regions F and F' may further comprise one or more DNA nucleosides.
[0174] Mixed winged gapmer designs are disclosed in WO 2008 / 049085 and WO 2012 / 109395, both of which are incorporated herein by reference.
[0175] Alternating Flank Gappar The flanking regions may contain both LNA and DNA nucleosides and are referred to as "alternating flanks" because they contain an alternating motif of LNA-DNA-LNA nucleosides. Gapmers containing such alternating flanks are referred to as "alternating flank gapmers." Thus, an "alternating flank gapmer" is an LNA gapmer oligonucleotide in which at least one of the flanks (F or F') contains DNA in addition to LNA nucleosides. In some embodiments, at least one of regions F or F', or both regions F and F', contain both LNA and DNA nucleosides. In such embodiments, flanking regions F or F', or both F and F', contain at least three nucleosides and the 5' and 3' most nucleosides of the F and / or F' regions are LNA nucleosides.
[0176] Alternating flanking LNA gapmers are disclosed in WO 2016 / 127002.
[0177] The alternating flanking regions may contain up to three contiguous DNA, for example 1 to 2 or 1 or 2 or 3 contiguous DNA nucleosides.
[0178] The alternating flanks can be annotated, for example, as a series of integers representing the number of LNA nucleosides (L) followed by the number of DNA nucleosides (D), e.g. [L] 1-3 -[D] 1-4 -[L] 1-3 [L] 1-2 -[D] 1-2 -[L] 1-2 -[D] 1-2 -[L] 1-2 It is.
[0179] In oligonucleotide design, these are often represented as numbers such that 2-2-1 represents 5'[L]2-[D]2-[L]3' and 1-1-1-1-1 represents 5'[L]-[D]-[L]-[D]-[L]3'. The length of the flanks (regions F and F') of an oligonucleotide with alternating flanks can be independently 3 to 10 nucleosides, such as 4 to 8, such as 5 to 6 nucleosides, such as 4, 5, 6 or 7 modified nucleosides. In some embodiments, only one flank of a gapmer oligonucleotide is alternating, while the other is composed of LNA nucleotides. It can be advantageous to have at least two LNA nucleosides at the 3' end of the 3' flank (F') to confer additional exonuclease resistance. Some examples of oligonucleotides with alternating flanks are: TIFF2024160282000010.tif25128, with the proviso that the total length of the gapmer region is at least 12, such as at least 14 nucleotides in length.
[0180] Region D' or D" in the oligonucleotide The oligonucleotides of the invention may, in some embodiments, comprise or consist of a contiguous nucleotide sequence of the oligonucleotide that is complementary to a target nucleic acid, such as a gapmer FG-F', as well as additional 5' and / or 3' nucleosides. The additional 5' and / or 3' nucleosides may or may not be fully complementary to the target nucleic acid. Such additional 5' and / or 3' nucleosides may be referred to herein as regions D' and D".
[0181] The addition of region D' or D" can be used for the purpose of linking a contiguous nucleotide sequence, such as a gapmer, to a conjugate moiety or other functional group. When used to link a conjugate moiety to a conjugate moiety, it can serve as a biocleavable linker. Alternatively, it can be used to provide exonuclease protection or to facilitate synthesis or manufacturing.
[0182] Regions D' and D" can be attached to the 5' end of region F or the 3' end of region F', respectively, to generate designs of the following formula D'-FG-F', FG-F'-D" or D'-FG-F'-D", where FG-F' is the gapmer portion of the oligonucleotide and regions D' or D" constitute separate portions of the oligonucleotide.
[0183] Regions D' or D" independently comprise or consist of 1, 2, 3, 4 or 5 additional nucleotides and may or may not be complementary to the target nucleic acid. The nucleotides adjacent to the F or F' region are not sugar-modified nucleotides but are, for example, DNA or RNA or base-modified versions thereof. The D' and D" regions may serve as nuclease-sensitive biocleavable linkers (see definition of linker). In some embodiments, the additional 5' and / or 3' terminal nucleotides are linked by phosphodiester bonds and are DNA or RNA. Nucleotide-based biocleavable linkers suitable for use as regions D' and D" are disclosed in WO 2014 / 076195, which include, as examples, phosphodiester-linked DNA dinucleotides. The use of biocleavable linkers in polyoligonucleotide constructs is disclosed in WO 2015 / 113922, where they have been used to join multiple antisense constructs (e.g., gapmer regions) within a single oligonucleotide.
[0184] In one embodiment, the oligonucleotide of the invention comprises regions D' and / or D" in addition to the contiguous nucleotide sequence that constitutes the gapmer.
[0185] In some embodiments, the oligonucleotides of the invention can be represented by the following formula: FG-F'; especially F 1-8 -G 5-16 -F' 2-8 D'-FG-F', especially D' 1-3 -F 1-8 -G 5-16 -F' 2-8 FG-F'-D'', especially F 1-8 -G 5-16 -F' 2-8 -D'' 1-3 D'-FG-F'-D'', especially D' 1-3 -F 1-8 -G 5-16 -F' 2-8 -D'' 1-3
[0186] In some embodiments, the internucleoside linkage located between region D' and region F is a phosphodiester linkage. In some embodiments, the internucleoside linkage located between region F' and region D" is a phosphodiester linkage.
[0187] Totalmer In some embodiments, all of the nucleosides of the oligonucleotide, or of the contiguous nucleotide sequence thereof, are sugar-modified nucleosides. Such oligonucleotides are referred to herein as totalmers.
[0188] In some embodiments, all of the sugar modified nucleosides of a totalmer comprise the same sugar modification, for example, they may be all LNA nucleosides or all 2'O-MOE nucleosides. In some embodiments, the sugar modified nucleosides of a totalmer may be independently selected from LNA nucleosides and 2' substituted nucleosides, such as 2' substituted nucleosides selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA, and 2'-F-ANA nucleosides. In some embodiments, the oligonucleotide comprises both LNA nucleosides and 2'-substituted nucleosides, such as 2'-substituted nucleosides selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA, and 2'-F-ANA nucleosides. In some embodiments, the oligonucleotide comprises LNA nucleosides and 2'-O-MOE nucleosides. In some embodiments, the oligonucleotide comprises (S)cET LNA nucleosides and 2'-O-MOE nucleosides. In some embodiments, each nucleoside unit of the oligonucleotide is a 2'-substituted nucleoside. In some embodiments, each nucleoside unit of the oligonucleotide is a 2'-O-MOE nucleoside.
[0189] In some embodiments, all nucleosides of the oligonucleotide or its contiguous nucleotide sequence are LNA nucleosides, such as β-D-oxy-LNA nucleosides and / or (S)cET nucleosides. In some embodiments, such LNA totalmer oligonucleotides are 7-12 nucleosides in length (see, for example, WO 2009 / 043353). Such short, all-LNA oligonucleotides are particularly effective in inhibiting microRNAs.
[0190] Various totalmer compounds are highly effective as therapeutic oligomers, especially when targeting microRNAs (antimiRs) or as splice-switching oligomers (SSOs).
[0191] In some embodiments, a totalmer comprises or consists of at least one XYX or YXY sequence motif, such as the repeated sequence XYX or YXY, where X is LNA and Y is an alternative (i.e., non-LNA) nucleotide analogue, such as 2'-OMe RNA units and 2'-fluoro DNA units. The above sequence motifs can be, for example, XXY, XYX, YXY or YYX in some embodiments.
[0192] In some embodiments, a totalmer may comprise or consist of a contiguous nucleotide sequence of 7 to 24 nucleotides, such as 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 nucleotides.
[0193] In some embodiments the contiguous nucleotide sequence of the totalmer comprises at least 30%, such as at least 40%, for example at least 50%, such as at least 60%, for example at least 70%, for example at least 80%, such as at least 90%, for example 95%, for example 100% LNA units. Advantageously the complete LNA compound is less than 12 nucleotides in length, for example 7-10.
[0194] The remaining units may be selected from the non-LNA nucleotide analogues mentioned herein, such as those selected from the group consisting of 2'-O-alkyl-RNA units, 2'-OMe-RNA units, 2'-amino-DNA units, 2'-fluoro-DNA units, LNA units, PNA units, HNA units, INA units, and 2'MOE RNA units, or the group of 2'-OMe RNA units and 2'-fluoro DNA units.
[0195] Mixmar The term "mixmer" refers to an oligomer that contains both DNA nucleosides and sugar-modified nucleosides, where the length of consecutive DNA nucleosides is insufficient to recruit RNaseH. Suitable mixmers may contain up to three or up to four consecutive DNA nucleosides. In some embodiments, the mixmer contains alternating regions of sugar-modified nucleosides and DNA nucleosides. Non-RNaseH recruiting oligonucleotides can be created by alternating regions of sugar-modified nucleosides that form an RNA-like (3'-endo) conformation when incorporated into an oligonucleotide with short regions of DNA nucleosides. Advantageously, the sugar-modified nucleoside is an affinity-enhancing sugar-modified nucleoside.
[0196] Oligonucleotide mixmers are often used to provide activity-based regulation of target genes, such as splice modulators and microRNA inhibitors.
[0197] In some embodiments, the sugar modified nucleosides in a mixmer, or the contiguous nucleotide sequence thereof, comprise or are all LNA nucleosides, such as (S)cET or β-D-oxyLNA nucleosides.
[0198] In some embodiments, all of the sugar-modified nucleosides of a mixmer contain the same sugar modification, e.g., they may all be LNA nucleosides or all 2'O-MOE nucleosides. In some embodiments, the sugar-modified nucleosides of a mixmer may be independently selected from LNA nucleosides and 2'-substituted nucleosides, e.g., 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA, and 2'-F-ANA nucleosides. In some embodiments, the oligonucleotide comprises both an LNA nucleoside and a 2'-substituted nucleoside, such as a 2'-substituted nucleoside selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA, and 2'-F-ANA nucleoside. In some embodiments, the oligonucleotide comprises an LNA nucleoside and a 2'-O-MOE nucleoside. In some embodiments, the oligonucleotide comprises an (S)cET LNA nucleoside and a 2'-O-MOE nucleoside.
[0199] In some embodiments, the mixmer or its contiguous nucleotide sequence contains only LNA and DNA nucleosides, and such LNA mixmer oligonucleotides can be, for example, 8 to 24 nucleosides in length (see, for example, WO2007112754, which discloses LNA antmiR inhibitors of microRNA).
[0200] Various mixmer compounds have demonstrated high efficacy as therapeutic oligomers, particularly when targeting microRNAs (antimiRs) or as splice-switching oligomers (SSOs).
[0201] In some embodiments, the mixmer comprises the following motif: TIFF2024160282000011.tif36128
[0202] wherein L represents a sugar-modified nucleoside such as LNA or a 2'-substituted nucleoside (e.g., 2'-O-MOE), D represents a DNA nucleoside, each m is independently selected from 1-6, and each n is independently selected from 1, 2, 3, and 4, e.g., 1-3. In some embodiments, each L is an LNA nucleoside. In some embodiments, at least one L is an LNA nucleoside and at least one L is a 2'-O-MOE nucleoside. In some embodiments, each L is independently selected from an LNA and a 2'-O-MOE nucleoside.
[0203] In some embodiments, a mixmer may comprise or consist of a contiguous nucleotide sequence of 10 to 24 nucleotides, such as 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 nucleotides.
[0204] In some embodiments the contiguous nucleotide sequence of the mixmer comprises at least 30%, such as at least 40%, such as at least 50% LNA units.
[0205] In some embodiments, the mixmer comprises or consists of a continuous nucleotide sequence of a repeating pattern of nucleotide analogs and naturally occurring nucleotides, or one type of nucleotide analog and a second type of nucleotide analog. The repeating pattern can be, for example, as follows: every other or every third nucleotide is a nucleotide analog such as LNA, and the remaining nucleotides are naturally occurring nucleotides such as DNA, or 2'-substituted nucleotide analogs such as 2'MOE of 2'fluoro analogs as mentioned herein, or in some embodiments selected from the group of nucleotide analogs as mentioned herein. It is recognized that the repeating pattern of nucleotide analogs such as LNA units can be combined with nucleotide analogs at fixed positions, for example, at the 5' or 3' ends.
[0206] In some embodiments, the first nucleotide of the oligomer, counting from the 3' end, is a nucleotide analog, such as an LNA nucleotide or a 2'-O-MOE nucleoside.
[0207] In some embodiments, which may be the same or different, the second nucleotide of the oligomer, counting from the 3' end, is a nucleotide analog, such as an LNA nucleotide or a 2'-O-MOE nucleoside.
[0208] In some embodiments, which may be the same or different, the 5' end of the oligomer is a nucleotide analog, such as an LNA nucleotide or a 2'-O-MOE nucleoside.
[0209] In some embodiments the mixmer comprises at least one region comprising at least two consecutive nucleotide analogue units, such as at least two consecutive LNA units.
[0210] In some embodiments the mixmer comprises a region comprising at least three consecutive nucleotide analogue units, such as at least three consecutive LNA units.
[0211] Conjugates The term conjugate, as used herein, refers to an oligonucleotide covalently attached to a non-nucleotide moiety (the conjugate moiety or region C or the third region).
[0212] Conjugation of the oligonucleotide of the present invention to one or more non-nucleotide moieties can improve the pharmacology of the oligonucleotide, for example, by affecting the activity, cellular distribution, cellular uptake, or stability of the oligonucleotide.In some embodiments, the conjugate moiety regulates or improves the pharmacokinetic properties of the oligonucleotide by improving the cellular distribution, bioavailability, metabolism, excretion, permeability, and / or cellular uptake of the oligonucleotide.In particular, the conjugate can target the oligonucleotide to a specific organ, tissue, or cell type, thereby enhancing the efficacy of the oligonucleotide in that organ, tissue, or cell type.At the same time, the conjugate can help to reduce the activity of the oligonucleotide in non-target cell types, tissues, or organs (e.g., off-target activity or activity in non-target cell types, tissues, or organs).
[0213] WO 93 / 07883 and WO 2013 / 033230 provide suitable conjugate moieties, which are incorporated herein by reference. Further suitable conjugate moieties are those that can bind to asialoglycoprotein receptor (ASGPR). In particular, trivalent N-acetylgalactosamine conjugate moieties are suitable for binding to ASGPR, see, for example, WO 2014 / 076196, WO 2014 / 207232 and WO 2014 / 179620, which are incorporated herein by reference. Such conjugates promote the uptake of oligonucleotides into the liver while reducing their presence in the kidney, thereby increasing the liver / kidney ratio of conjugated oligonucleotides compared to unconjugated versions of the same oligonucleotides.
[0214] Oligonucleotide conjugates and their synthesis are also reported in comprehensive reviews by Manoharan in Antisense Drug Technology, Principles, Strategies, and Applications, STCrooke, ed., Ch. 16, Marcel Dekker, Inc., 2001 and Manoharan, Antisense and Nucleic Acid Drug Development, 2002, 12, 103, each of which is incorporated herein by reference in its entirety.
[0215] In one embodiment, the non-nucleotide moiety (conjugate moiety) is selected from the group consisting of a carbohydrate, a cell surface receptor ligand, a drug substance, a hormone, a lipophile, a polymer, a protein, a peptide, a toxin (e.g., a bacterial toxin), a vitamin, a viral protein (e.g., a capsid), or a combination thereof.
[0216] Linker Linkage or linker is the connection between two atoms that connects a chemical group or segment of interest to another chemical group or segment through one or more covalent bonds.The conjugate moiety can be directly or through a linking moiety (e.g., linker or tether) to the oligonucleotide.The linker serves to covalently link the third region, e.g., the conjugate moiety (region C), to the first region, e.g., the oligonucleotide or continuous nucleotide sequence (region A) that is complementary to the target nucleic acid.
[0217] In some embodiments of the invention, the conjugates or oligonucleotide conjugates of the invention may optionally comprise a linker region (second region or region B and / or region Y) located between the oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A or first region) and the conjugate moiety (region C or third region).
[0218] Region B refers to a biocleavable linker that comprises or consists of a physiologically labile bond that is cleavable under conditions similar to those normally encountered or encountered in a mammalian body. Conditions under which a physiologically labile linker undergoes chemical transformation (e.g., cleavage) include chemical conditions such as pH, temperature, oxidative or reductive conditions or agents, and salt concentrations similar to those found or encountered in mammalian cells. Mammalian intracellular conditions also include the presence of enzymatic activities normally present in mammalian cells, such as proteolytic or hydrolytic enzymes or nucleases. In one embodiment, the biocleavable linker is susceptible to S1 nuclease cleavage. In a preferred embodiment, the nuclease-sensitive linker comprises 1 to 10 nucleosides, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleosides, more preferably 2 to 6 nucleosides, and most preferably 2 to 4 linked nucleosides, comprising at least two consecutive phosphodiester bonds, at least three or four or five consecutive phosphodiester bonds. Preferably, the nucleoside is DNA or RNA. Phosphodiester-containing biocleavable linkers are described in more detail in WO 2014 / 076195, which is incorporated herein by reference.
[0219] Region Y refers to a linker that is not necessarily biocleavable but serves primarily to covalently attach the conjugate moiety (region C or third region) to the oligonucleotide (region A or first region). Region Y linkers may include chain structures or oligomers of repeating units such as ethylene glycol, amino acid units or aminoalkyl groups. The oligonucleotide conjugates of the invention may be composed of the following region elements AC, ABC, ABYC, AYBC or AYC. In some embodiments, the linker (region Y) is an aminoalkyl, such as, for example, a C2-C36 aminoalkyl group, including a C6-C12 aminoalkyl group. In a preferred embodiment, the linker (region Y) is a C6 aminoalkyl group.
[0220] Thus, the oligonucleotide according to the invention has the formula (II) TIFF2024160282000012.tif28128[where, (A 1 ) and (A 2 ) are as defined above] It is of the following.
[0221] Thus, the present invention relates in particular to:
[0222] Nucleoside (A 1 ) is a DNA nucleoside;
[0223] Nucleoside (A 2 ) is a DNA nucleoside, an RNA nucleoside or a sugar-modified nucleoside;
[0224] Nucleoside (A 2 ) is a DNA nucleoside or a sugar-modified nucleoside;
[0225] the oligonucleotide according to the invention, wherein the sugar-modified nucleoside is a 2' sugar-modified nucleoside;
[0226] Nucleoside (A 2 ) is 2'-alkoxy-RNA, in particular 2'-methoxy-RNA, 2'-alkoxyalkoxy-RNA, in particular 2'-methoxyethoxy-RNA, 2'-amino-DNA, 2'-fluoro-RNA or 2'-fluoro-ANA;
[0227] Nucleoside (A 2 ) is an LNA nucleoside;
[0228] an oligonucleotide according to the invention, wherein the LNA nucleosides are independently selected from β-D-oxy LNA, 6'-methyl-β-D-oxy LNA and ENA, in particular β-D-oxy LNA;
[0229] Nucleoside (A 1 ) and (A 2 the oligonucleotide according to the present invention, wherein at least one of
[0230] The oligonucleotide according to the invention, wherein the 2'-alkoxyalkoxy-RNA is 2'-methoxyethoxy-RNA;
[0231] Nucleoside (A 1 ) and (A 2 ) are both DNA nucleosides;
[0232] an oligonucleotide according to the invention comprising further internucleoside linkages selected from phosphodiester internucleoside linkages of formula (I) as defined above, phosphorothioate internucleoside linkages and phosphorotrithioate internucleoside linkages;
[0233] an oligonucleotide according to the invention comprising further internucleoside linkages selected from phosphorothioate internucleoside linkages of formula (I) and phosphorotrithioate internucleoside linkages as defined above;
[0234] an oligonucleotide according to the invention comprising 1 to 15, in particular 1 to 5, more in particular 1, 2, 3, 4 or 5 phosphorotrithioate internucleoside linkages of formula (I) as defined above;
[0235] All further internucleoside bonds are Formula -P(=S)(OR)O2-, where R is as defined above. the oligonucleotide according to the invention, wherein the phosphorothioate internucleoside linkage is:
[0236] an oligonucleotide according to the invention comprising a further nucleoside selected from DNA nucleosides, RNA nucleosides and sugar-modified nucleosides;
[0237] an oligonucleotide according to the invention, wherein one or more nucleosides are nucleobase modified nucleosides;
[0238] The oligonucleotide according to the invention, wherein the oligonucleotide is an antisense oligonucleotide, an siRNA, a microRNA mimetic or a ribozyme;
[0239] The oligonucleotide according to the invention, wherein the oligonucleotide is an antisense gapmer oligonucleotide;
[0240] an oligonucleotide according to the invention, wherein the phosphorotrithioate internucleoside linkage of formula (I) is in the gap region of the gapmer oligonucleotide;
[0241] An oligonucleotide according to the invention, wherein the gapmer oligonucleotide is an LNA gapmer, a mixed wing gapmer or a 2' substituted gapmer, in particular a 2'-O-methoxyethyl gapmer;
[0242] an oligonucleotide according to the invention, wherein the gapmer oligonucleotide comprises a contiguous nucleotide sequence of the formula 5'-FG-F'-3', where G is a region of 5 to 18 nucleosides capable of recruiting RnaseH, said region G being flanked at 5' and 3' by flanking regions F and F', respectively, and regions F and F' independently comprise or consist of 1 to 7 2' sugar-modified nucleotides, wherein the nucleosides of region F adjacent to region G are 2' sugar-modified nucleosides and the nucleosides of region F' adjacent to region G are 2' sugar-modified nucleosides;
[0243] a gapmer oligonucleotide according to the invention, wherein said at least one phosphorotrithioate internucleoside linkage of formula (I) as defined above is located between adjacent nucleosides of region G or between region G and region F';
[0244] An oligonucleotide according to the invention, wherein the oligonucleotide is an antisense oligonucleotide mixmer or totalmer, in particular a splice switching oligonucleotide or a microRNA inhibitor oligonucleotide;
[0245] 2. A pharma- ceutically acceptable salt of the oligonucleotide according to the invention, in particular the sodium or potassium salt;
[0246] a conjugate comprising an oligonucleotide or a pharma- ceutically acceptable salt according to the invention and at least one conjugate moiety covalently attached to said oligonucleotide or said pharma- ceutically acceptable salt, optionally via a linker moiety;
[0247] A pharmaceutical composition comprising an oligonucleotide according to the invention, a pharma- ceutically acceptable salt or conjugate, and a therapeutically inert carrier;
[0248] an oligonucleotide, a pharma- ceutically acceptable salt or a conjugate according to the invention for use as a therapeutically active substance;
[0249] an oligonucleotide, a pharma- ceutically acceptable salt or conjugate thereof according to the invention for use in the treatment or prevention of cardiac or hematological diseases;
[0250] Use of an oligonucleotide, a pharma- ceutically acceptable salt or a conjugate according to the invention for the preparation of a medicament for the treatment or prevention of cardiac or hematological diseases;
[0251] Use of an oligonucleotide, a pharma- ceutically acceptable salt or a conjugate according to the invention in the treatment or prevention of cardiac or hematological diseases;
[0252] A method for the treatment or prevention of cardiac or blood disorders, comprising administering to a patient in need thereof an effective amount of an oligonucleotide, a pharma- ceutically acceptable salt or conjugate according to the invention;
[0253] A method for inhibiting a target RNA in a cell, in particular a human mRNA or a viral RNA, comprising administering an oligonucleotide according to the invention to a cell expressing said target RNA;
[0254] an in vitro method of modulating or inhibiting a target RNA, in particular a human mRNA or a viral RNA, in a cell, comprising administering an oligonucleotide or a gapmer oligonucleotide according to the invention to a cell expressing said target RNA;
[0255] A method for producing an oligonucleotide according to the invention, comprising the steps of: (a) coupling a 3'S-modified nucleoside phosphoramidite to the terminal 5' sulfur atom of a 5'S-modified nucleoside or oligonucleotide to form a dithiophosphite triester intermediate; (b) thioxidizing the dithiophosphite triester intermediate obtained in step a); and (c) optionally further extending said oligonucleotide;
[0256] A method according to the invention, comprising attaching the 5'S-modified nucleoside or oligonucleotide of step (a) to a solid support;
[0257] A method according to the invention, further comprising cleavage of the oligonucleotide from the solid support; and
[0258] An oligonucleotide produced according to the method of the present invention.
[0259] In some embodiments, the oligonucleotide of the present invention has a higher activity in modulating its target nucleic acid compared to the corresponding fully phosphorothioate-linked oligonucleotide. In some embodiments, the present invention provides oligonucleotides with enhanced activity, enhanced potency, enhanced specific activity, or enhanced cellular uptake. In some embodiments, the present invention provides oligonucleotides with altered duration of action in vitro or in vivo, such as extended duration of action in vitro or in vivo. In some embodiments, the higher activity in modulating the target nucleic acid is determined in vitro or in vivo in cells expressing the target nucleic acid.
[0260] In some embodiments, the oligonucleotides of the present invention have altered pharmacological properties, such as reduced toxicity, e.g., reduced nephrotoxicity, reduced hepatotoxicity, or reduced immune stimulation. Hepatotoxicity can be determined, for example, in vivo or by using the in vitro assays disclosed in WO 2017 / 067970, which is incorporated herein by reference. Nephrotoxicity can be determined, for example, in vitro or by using the assays disclosed in PCT / EP2017 / 064770, which is incorporated herein by reference. In some embodiments, the oligonucleotides of the present invention comprise a 5' CG 3' dinucleotide, e.g., a DNA 5' CG 3' dinucleotide, in which the internucleoside linkage between C and G is a phosphorotrithioate internucleoside linkage of formula (I) as defined above.
[0261] In some embodiments, the oligonucleotide of the present invention has improved nuclease resistance, for example improved biostability in serum.In some embodiments, the 3'-terminal nucleoside of the oligonucleotide of the present invention has A or G base, for example 3'-terminal LNA-A or LNA-G nucleoside.Suitably, the internucleoside bond between the two most 3' nucleosides of the oligonucleotide can be a phosphorotrithioate internucleoside bond according to formula (I) defined above.
[0262] In some embodiments, the oligonucleotides of the invention have enhanced bioavailability, hi some embodiments, the oligonucleotides of the invention have greater blood exposure, e.g., longer blood residence time.
[0263] The oligonucleotide according to the present invention can be prepared, for example, according to the following scheme.
[0264] Trithiophosphate bonds with sulfur atoms at the non-bridging position as well as at the 3' and 5' positions of the adjacent furanose ring can be introduced into oligonucleotides by solid-phase synthesis using the phosphoramidite method. The synthesis was carried out using controlled pore glass (CPG) with a universal linker as the support. On such solid supports, oligonucleotides are typically constructed in the 3'-5' direction by successive cycles of coupling of 5'O-DMT-protected nucleoside phosphoramidite building blocks followed by (thio)oxidation, capping and deprotection of the DMT group. For the introduction of phosphorotrithioates as described in this application, a DMT-protected 5'-deoxy-5'-mercapto phosphoramidite building block is attached to the free 5'-hydroxy group of the solid support-bound oligonucleotide chain. After (thio)oxidation and capping, the resulting intermediate is deprotected to liberate the 5'-thiol group.
[0265] Scheme 1 TIFF2024160282000013.tif68133
[0266] This deprotection is difficult and is best accomplished by either repeatedly (15 or more times) applying standard deprotection conditions (typically 3-5% dichloroacetic or trichloroacetic acid in dichloromethane) or by using higher acid concentrations (e.g. up to 10% trichloroacetic acid in dichloromethane) or stronger acids (e.g. 5% trifluoroacetic acid in dichloromethane), preferentially with the use of appropriate cation scavengers (typically triethylsilane 20%, 4-methoxythiophenol 5% or a combination of both).
[0267] Scheme 2 TIFF2024160282000014.tif35147
[0268] The free 5' thiol group thus obtained is then coupled to the appropriate 5'O-DMT protected 3'-deoxy-3'-mercapto phosphoramidite building block. Due to the low reactivity of such building blocks, a typical procedure involves 12 couplings using 4 equivalents and a long reaction time (7.5 min). The resulting dithiophosphite intermediate can then be thioxidated using a suitable reagent (e.g., 3-amino-1,2,4-dithiazole-5-thione) to provide the desired phosphorotrithioate linkage.
[0269] Scheme 3 TIFF2024160282000015.tif69153
[0270] In the above scheme: R 2a and R 4a together form -XY- as defined above, or R 4a is hydrogen and R 2a is selected from alkoxy, in particular methoxy, halogen, in particular fluoro, alkoxyalkoxy, in particular methoxyethoxy, alkenyloxy, in particular allyloxy and aminoalkoxy, in particular aminoethyloxy, R2b and R 4b together form -XY- as defined above, or R 2b and R 4b are both hydrogen at the same time, or R 4b is hydrogen and R 2b is selected from alkoxy, in particular methoxy, halogen, in particular fluoro, alkoxyalkoxy, in particular methoxyethoxy, alkenyloxy, in particular allyloxy and aminoalkoxy, in particular aminoethyloxy, R 3 is dialkylamino or pyrrolidinyl, R 5 is a hydroxyl or thiohydroxyl protecting group, R is as defined above.
[0271] The invention will now be illustrated by the following examples, which have no limiting character. EXAMPLES
[0272] Example 1 Oligonucleotide synthesis Oligonucleotides were synthesized using a MerMade 12 automated DNA synthesizer from Bioautomation, Inc. Synthesis was performed on a 1 μmol scale using controlled pore glass supports (500 Å) equipped with universal linkers.
[0273] In the standard cycling procedure for coupling of DNA and LNA phosphoramidites, DMT deprotection was performed using 3% (w / v) trichloroacetic acid in CHCl, applying 200 μL three times for 30 s. 100 μL of a 0.1 M solution in acetonitrile (or LNA- MeEach phosphoramidite was coupled three times using acetonitrile / CHCl 1:1 for the C building block, 110 μL of a 0.1 M solution of 5-(3,5-bis(trifluoromethylphenyl))-1H-tetrazole in acetonitrile as activator, and a coupling time of 180 s. For thioxidation, a 0.1 M solution of 3-amino-1,2,4-dithiazole-5-thione in acetonitrile / pyridine 1:1 was used (3 × 190 μL, 55 s). Capping was performed for 55 s using THF / lutidine / AcO 8:1:1 (CapA, 75 μmol) and THF / N-methylimidazole 8:2 (CapB, 75 μmol).
[0274] The synthesis cycle for incorporating the 2',3'-dideoxy-3'-mercaptophosphoramidite included DMT deprotection using 3% (w / v) trichloroacetic acid in CHCl, 200 μL applied three times for 30 s. Ten phosphoramidite couplings were performed with a coupling time of 900 s using 40 μL of a 0.1 M solution in acetonitrile and 44 μL of a 0.1 M solution of 5-(3,5-bis(trifluoromethylphenyl))-1H-tetrazole in acetonitrile. Thioxidation was performed immediately after coupling by applying 190 μL of a 0.1 M solution of 3-amino-1,2,4-dithiazole-5-thione in acetonitrile / pyridine 1:1 three times for 55 s. Capping was performed for 55 s using THF / lutidine / Ac2O 8:1:1 (CapA, 75 μmol) and THF / N-methylimidazole 8:2 (CapB, 75 μmol).
[0275] The synthesis cycle for incorporating 2',5'-dideoxy-5'-mercaptophosphoramidites included coupling of the phosphoramidite building blocks using 100 μL of a 0.1 M solution in acetonitrile and 110 μL of a 0.1 M solution of 5-(3,5-bis(trifluoromethylphenyl))-1H-tetrazole in acetonitrile with a coupling time of 180 s. Triple coupling was performed. Thioxidation was performed using a 0.1 M solution of 3-amino-1,2,4-dithiazole-5-thione in acetonitrile / pyridine 1:1 (3 × 190 μL, 55 s). For capping, THF / lutidine / Ac2O 8:1:1 (CapA, 75 μmol) and THF / N-methylimidazole 8:2 (CapB, 75 μmol) were applied for 55 s. DMT deprotection and release of thiols was performed with 3% (w / v) trichloroacetic acid in CHCl using 15 applications of 200 μL for 30 s. DMT deprotection and release of thiols was also advantageously performed with 3-6 applications of 200 μL of 1-10% (v / v) trifluoroacetic acid or 5-10% (w / v) trichloroacetic acid for 45 s in the presence of 5-30% (v / v) triethylsilane in CHCl and / or 2-10% p-methoxythiophenol in CHCl.
[0276] Removal of the nucleobase protecting groups and cleavage from the solid support was accomplished under standard conditions with 32% aqueous ammonia for a minimum of 8 hours at 55° C. The crude DMT-on oligonucleotides were either repurified by ion exchange chromatography using solid phase extraction cartridges or purified by RP-HPLC purification using a C18 column followed by DMT removal with 80% aqueous acetic acid and ethanol precipitation.
[0277] Following the general procedures above, the following molecules were prepared: TIFF2024160282000016.tif104159 Trithioate modifications between bold and underlined nucleotides A, G, m C and T represent LNA nucleotides. a, g, c, t represent DNA nucleotides. All other linkages were prepared as phosphorothioates.
[0278] Compounds #1-8 are based on SEQ ID NO: 1. They differ in the position of the phosphorotrithioate internucleoside linkage of formula (I), as shown in the table above.
[0279] Example 2 In vitro mRNA reduction and intracellular concentration (uptake) Primary rat hepatocytes were plated in 96-well plates and treated with Williams' medium E containing 10% FCS without the addition of antibiotics. The cells were treated with the indicated concentrations of LNA solutions in complete cell culture medium. After incubation times of 24 and 72 h, respectively, the cells were incubated with Ca 2+ and Mg 2+ The cells were washed three times with PBS containing 0.1% ethanol and lysed in 165 μL of PureLink Pro Lysis Buffer. Total RNA was isolated using Thermo Fisher's PureLink PRO96 RNA Kit according to the manufacturer's instructions, and RT-qPCR was performed using the LightCycler Multiplex RNA Virus Master (Roche) with a primer probe set for RnApoB (Invitrogen). Data obtained were normalized to Ribogreen.
[0280] Intracellular concentrations of LNA oligonucleotides were determined using a hybridization-based ELISA assay. All data points were performed in duplicate and data are presented as the average.
[0281] The results are shown in Figure 1.
[0282] As can be seen from the data, the modifications according to the invention are very well tolerated and the oligonucleotides show good potency as well as adequate intracellular concentrations.
[0283] Example 3 In vivo mRNA depletion in liver and kidney C57BL / 6JBomTac female mice weighing approximately 20 grams received a single dose of 1 mg / kg at a concentration of 0.1 mg / kg in a volume of 10 ml / kg on day 0 and animals were sacrificed on day 7. Serum, liver, kidney and heart tissues were harvested at termination.
[0284] mRNA analysis from tissues was performed using the Qantigene mRNA quantification kit ("bDNA-assay", Panomics / Affymetrix) according to the manufacturer's protocol. For tissue lysates, 50-80 mg of tissue was sonicated in 1 ml of lysis buffer containing proteinase K. Lysates were used directly for bDNA assays without RNA extraction. Target and GAPDH probe sets were custom designed and obtained from Panomics. For analysis, luminescence units obtained for the target genes were normalized to the housekeeper GAPDH.
[0285] The results are shown in Figure 2.
[0286] Figure 2 shows improved target reduction in the liver for oligonucleotides having modifications according to the invention compared to unmodified phosphorothioate controls. These findings are all the more surprising in light of the fact that this particular molecule showed the lowest in vitro target reduction of this series.
[0287] Example 4 Serum cholesterol level C57BL / 6JBomTac female mice weighing approximately 20 grams received a single dose of 1 mg / kg at a concentration of 0.1 mg / kg in a volume of 10 ml / kg on day 0 and animals were sacrificed on day 7. Serum, liver, kidney and heart tissues were harvested at termination.
[0288] Serum analysis for cholesterol was performed using 10 μl of serum on the “Cobas INTEGRA 400plus” clinical chemistry platform (Roche Diagnostics).
[0289] The results are shown in Figure 3.
[0290] The data demonstrate that the observed higher target reduction of oligonucleotides with modifications according to the invention (Figure 2, Example 3) results in improved reduction of serum cholesterol levels, which is a functional readout of activity against this particular sequence. These findings are all the more surprising in light of the fact that this particular molecule showed the lowest in vitro target reduction of this series.
[0291] Example 5 In vivo tissue uptake in liver, kidney, and heart C57BL / 6JBomTac female mice weighing approximately 20 grams received a single dose of 1 mg / kg at a concentration of 0.1 mg / kg in a volume of 10 ml / kg on day 0 and animals were sacrificed on day 7. Serum, liver, kidney and heart tissues were harvested at termination.
[0292] For oligonucleotide quantification, fluorescently labeled PNA probes are hybridized to the oligos of interest in tissue lysates. The same lysates as for the bDNA assay were used, only weighted accurately for the amount of tissue. Heteroduplexes are quantified using AEX-HPLC and fluorescence detection.
[0293] The results are shown in Figure 4.
[0294] Figure 4 demonstrates the beneficial effect of the modifications according to the invention on tissue uptake. The data show not only high tissue content in the liver and kidney, but also the surprising potential of this modification to improve tissue distribution to the heart. These findings are even more surprising in light of the fact that this particular molecule showed the lowest in vitro target reduction of this series.
[0295] Sequence information SEQUENCE LISTING <110> Roche Innovation Center Copenhagen A / S <120> Oligonucleotides comprising a phosphorotrithioate internucleoside linkage <150> EP 18186677.3 <151> 2018-07-31 <160> 1 <170> PatentIn version 3.5 <210> 1 <211> 13 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Construct <400> 1 gcattggtat tca 13
Claims
1. Formula (I) wherein one of the two bridging sulfur atoms is a DNA nucleoside or an RNA nucleoside (A 1 ) and the other is bound to the 3' carbon atom of another nucleoside (A 2 ) and R is hydrogen or a phosphate protecting group. An oligonucleotide comprising at least one phosphorotrithioate internucleoside linkage of
2. The nucleoside (A 1 2. The oligonucleotide of claim 1, wherein:
3. The nucleoside (A 2 3. The oligonucleotide of claim 1 or 2, wherein:
4. The nucleoside (A 2 4. The oligonucleotide of claim 1 , wherein:
5. The oligonucleotide of claim 3 or 4, wherein the sugar-modified nucleoside is a 2' sugar-modified nucleoside.
6. The nucleoside (A 2 6. The oligonucleotide according to claim 1, wherein said nucleotide is 2'-alkoxy-RNA, in particular 2'-methoxy-RNA, 2'-alkoxyalkoxy-RNA, in particular 2'-methoxyethoxy-RNA, 2'-amino-DNA, 2'-fluoro-RNA or 2'-fluoro-ANA.
7. The nucleoside (A 2 6. The oligonucleotide of claim 1 , wherein:
8. The oligonucleotide of claim 7, wherein said LNA nucleosides are independently selected from β-D-oxy LNA, 6'-methyl-β-D-oxy LNA and ENA, in particular β-D-oxy LNA.
9. The nucleoside (A 1 ) and (A 2 2. The oligonucleotide of claim 1, wherein at least one of said first and second amino acids is 2'-alkoxyalkoxy-RNA.
10. The oligonucleotide of claim 9, wherein the 2'-alkoxyalkoxy-RNA is 2'-methoxyethoxy-RNA.
11. The nucleoside (A 1 ) and (A 2 5. The oligonucleotide of claim 1 , wherein both of said nucleotides are DNA nucleosides.
12. 12. The oligonucleotide according to any one of claims 1 to 11, comprising further internucleoside linkages selected from phosphodiester internucleoside linkages, phosphorothioate internucleoside linkages and phosphorotrithioate internucleoside linkages of formula (I) as defined in claim 1.
13. 13. The oligonucleotide according to any one of claims 1 to 12, comprising a further internucleoside linkage selected from phosphorothioate internucleoside linkages and phosphorotrithioate internucleoside linkages of formula (I) as defined in claim 1.
14. 14. The oligonucleotide according to any one of claims 1 to 13, comprising 1 to 15, in particular 1 to 5, more particularly 1, 2, 3, 4 or 5 phosphorotrithioate internucleoside linkages of formula (I) as defined in claim 1.
15. all of said further internucleoside linkages are Formula-P(=S)(OR)O 2 - in which R is as defined in claim 1.
15. The oligonucleotide of claim 1, wherein the phosphorothioate internucleoside linkage is:
16. 16. The oligonucleotide of any one of claims 1 to 15, comprising a further nucleoside selected from a DNA nucleoside, an RNA nucleoside and a sugar-modified nucleoside.
17. 17. The oligonucleotide of any one of claims 1 to 16, wherein one or more nucleosides are nucleobase-modified nucleosides.
18. The oligonucleotide of any one of claims 1 to 17, wherein the oligonucleotide is an antisense oligonucleotide, an siRNA, a microRNA mimetic or a ribozyme.
19. The oligonucleotide of claim 1 , wherein the oligonucleotide is an antisense gapmer oligonucleotide.
20. 20. The oligonucleotide of claim 19, wherein the phosphorotrithioate internucleoside linkage of formula (I) is in the gap region of the gapmer oligonucleotide.
21. The oligonucleotide of claim 19 or 20, wherein the gapmer oligonucleotide is an LNA gapmer, a mixed wing gapmer, or a 2'-substituted gapmer, in particular a 2'-O-methoxyethyl gapmer.
22. 22. The gapmer oligonucleotide of any one of claims 19 to 21, wherein the gapmer oligonucleotide comprises a linked nucleotide sequence of the formula 5'-F-G-F'-3', where G is a region of 5 to 18 nucleosides capable of recruiting RNase H, said region G is flanked on the 5' and 3' ends by flanking regions F and F', respectively, and regions F and F' independently comprise or consist of 1 to 7 2' sugar modified nucleotides, wherein the nucleosides of region F adjacent to region G are 2' sugar modified nucleosides and the nucleosides of region F' adjacent to region G are 2' sugar modified nucleosides.
23. 23. The gapmer oligonucleotide of claim 22, wherein at least one phosphorotrithioate internucleoside linkage of formula (I) defined in claim 1 is disposed between adjacent nucleosides of region G or between region G and region F'.
24. The oligonucleotide according to any one of claims 1 to 23, wherein the oligonucleotide is an antisense oligonucleotide mixmer or totalmer, in particular a splice switching oligonucleotide or a microRNA inhibitor oligonucleotide.
25. 25. A pharma- ceutically acceptable salt of an oligonucleotide according to any one of claims 1 to 24, in particular a sodium or potassium salt.
26. 26. A conjugate comprising an oligonucleotide or a pharma- ceutically acceptable salt according to any one of claims 1 to 25, and at least one conjugate moiety covalently attached to the oligonucleotide or the pharma- ceutically acceptable salt, optionally via a linker moiety.
27. 27. A pharmaceutical composition comprising an oligonucleotide according to any one of claims 1 to 26, a pharma- ceutically acceptable salt or conjugate, and a therapeutically inert carrier.
28. 27. An oligonucleotide, a pharma- ceutically acceptable salt or a conjugate according to any one of claims 1 to 26 for use as a therapeutically active substance.
29. 27. An oligonucleotide, a pharma- ceutically acceptable salt or conjugate according to any one of claims 1 to 26 for use in the treatment or prevention of cardiac or hematological diseases.
30. 30. Use of an oligonucleotide, a pharma- ceutically acceptable salt or a conjugate according to any one of claims 1 to 26 for the preparation of a medicament for the treatment or prevention of a cardiac or hematological disease.
31. 27. Use of an oligonucleotide, a pharma- ceutically acceptable salt or a conjugate according to any one of claims 1 to 26 in the treatment or prevention of a cardiac or blood disease.
32. A method for the treatment or prevention of cardiac or blood diseases, comprising administering to a patient in need thereof an effective amount of an oligonucleotide, pharma- ceutically acceptable salt or conjugate of any one of claims 1 to 26.
33. Steps below: (a) coupling a 3'S-modified nucleoside phosphoramidite to the terminal 5' sulfur atom of a 5'S-modified nucleoside or oligonucleotide to form a dithiophosphite triester intermediate; (b) thioxidizing the dithiophosphite triester intermediate obtained in step a); and (c) optionally further extending said oligonucleotide 27. A method for producing the oligonucleotide of any one of claims 1 to 26, comprising:
34. 34. An oligonucleotide produced according to the method of claim 33.
35. The invention described herein.
Citation Information
Patent Citations
5'-dithio modified oligonucleotides
JP1998503773A
Modified oligoribonucleotide analogs with enhances immunostimulatory activity
WO2006116458A2
